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Meta-analysis combines individual studies or trials to achieve one overall treat-
ment eect estimate and has come a long way since rst appearing within medical
literature 30 years ago.
Most articles examine how best to combine the individual trials and measure
the combined estimate. A lot of articles also examine the dierent sources of
variation, between study variation and within study variation, which occur when
performing a meta-analysis, and how 'best' to account for the between study
variation, the heterogeneity.
Very little information however, has been published on the relationship which
occurs between the treatment eect estimate and the heterogeneity. Most publi-
cations examine these two measures individually, assuming they are independent,
however further examination of this relationship brings this assumption of inde-
pendence into question.
We have examined the relationship of the treatment eect estimates and their
corresponding heterogeneities for 125 independent meta-analyses using the fre-
quentist approach and note that the results indicate a relationship is present.
iThis relationship will have a resulting eect on how one measures the treat-
ment eect estimates and their corresponding heterogeneity and is something that
is considered here, using a Bayesian approach, along with a few other Bayesian
modeling approaches.
Building on these Bayesian approaches, we consider whether a hierarchical
model which would allow a meta-analysis of meta-analyses can be produced.
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Introduction
1.1 Introduction
Many clinical trials, both past and present, aim to compare a new treatment
with either a placebo, or an existing treatment which is already on the market,
however they can often have results which are inconclusive. This may be because
too small a sample size has been used, which is perhaps due to a poor intake of
patients to the trial.
Even when a trial does appear to show a signicant result which favours the
new treatment, it is not necessarily considered for licensing, especially in the
United States of America, unless there is at least one other independent clinical
trial which also displays signicant results in favour of the new treatment. For
example, there is more convincing evidence if a trial in a dierent country obtains
the same result.
This reasoning strengthens the argument in favour of this new treatment over
1CHAPTER 1. INTRODUCTION 2
a placebo or any existing previous treatment by studying the same question on
more than one occasion. It is less than ideal however, to continue repeating un-
necessary clinical trials with the same new treatment until a signicant dierence
is notable. This is partially for ethical reasons to prevent either the trials contin-
uing indenitely, or failure to notice the new treatment producing a signicantly
negative eect on the patients' health, but mainly to prevent accepting a false
positive result in favour of the new treatment, which will occur in 5% of all trials.
1.2 Meta-Analysis
A meta-analysis is a statistical method which can be used to overcome these
problems by systematically combining the results from several individual trials
concerning the same treatment and similar constraints and formally summarising
the results. The concept of meta-analysis is rst known to have been used in the
early 1900's (Pearson, 1904) for the combination of studies of typhoid vaccine
eectiveness, before rst appearing in medical literature during the 1980's. It is
a technique which is becoming more frequently and widely used, as well as being
recognised as an important step within the medical world.
Combinations of various independent trials allows an average treatment eect
to be produced which will consequently have a greater precision than any of the
individual estimates. Using the combined average treatment eect, a single over-
all null hypothesis which assumes no dierence between the placebo/previouslyCHAPTER 1. INTRODUCTION 3
existing treatment and the new treatment can then be tested against an alterna-
tive hypothesis which declares a dierence.
This can prove useful for preventing any further unnecessary trials in view of
a signicant result which can determine early on (using the pre-existing clinical
trials) whether or not there is evidence of a signicant treatment dierence, be
this in favour of the new treatment or against it.
An area of great debate surrounds how best to model the overall treatment
eect estimate. Some statisticians believe the use of the xed eects model which
assumes the size of the treatment eect is equal for each trial is best, whereas
many believe the random eects model which allows the size of the treatment
eect to dier between trials should be implemented. This random eects model
will allow for two sources of variation, the within study variation which is also
incorporated in a xed eects model, and a dierent source of variation, that
which occurs between the trials, also known as the heterogeneity. If a random
eects model is produced and there is in fact no heterogeneity present, the results
obtained would be similar to the results obtained if using a xed eects model.
A common problem which one should be aware of when computing a meta-
analysis is a possibility of bias occurring and subsequently care must be taken
when computing a meta-analysis to avoid this bias as much as possible. Publica-
tion bias can occur if the researcher considers solely trial results which have been
published, since many trial results (most commonly those which indicate a null
result) fail to become published. The danger in publication bias is the majority
of trials which are published are generally large trials, which can demonstrateCHAPTER 1. INTRODUCTION 4
either a signicant treatment eect or a non-signicant treatment eect, since it
is the large trials which are usually of most interest. Very few, if any, are small
trials, and of the small trials which are published they are usually only published
because they are signicant. To overcome this form of bias, the researcher should
ensure all studies are included in the meta-analysis as far as possible which may
involve searching for studies which are unpublished. Registering a trial with a
central register enables the trial to be tracked and allows the public to have ac-
cess to it. At present it is recommended that every trial is registered, for both
ethical reason and to attempt to prevent publication bias, however it is still not
yet compulsory.
1.3 Bayesian Methods
There is a lot of debate about the `best' way in which to model meta-analyses,
which can roughly be categorised into either the frequentist approach or the
Bayesian approach.
The frequentist approach uses solely the data that are provided, which can
be in any form, e.g. individual patient level data, and calculates an overall single
xed estimate for the treatment eect. This can then be tested against a null
hypothesis of there being no treatment dierence for a trial which is being used
to determine whether the new treatment is superior to the current treatment.
The treatment eect estimate in this case, which is an unknown parameter, is
treated as an unknown constant.CHAPTER 1. INTRODUCTION 5
The Bayesian approach however, allows the parameters, in this instance the
treatment eect and its variation, to be treated as random variables. Each of the
random variables in the model are given prior distributions \a reasonable opinion
concerning the plausibility of dierent values of the treatment eect excluding the
evidence from the trial" (Spiegelhalter et al., 2004) which can be informative, if
one has a subjective opinion of the prior information for a random variable, or
non-informative if one has no subjective prior belief concerning the parameter
in question. Generally if one has no prior belief concerning the behaviour of a
specied prior, one would model that specic variable as a non-informative prior.
The priors are combined with the likelihood \the support for dierent values
of the treatment eect based solely on data from the trial" (Spiegelhalter et al.,
2004), calculated from the data itself and this resulting combination produces the
posterior distribution \a nal opinion about the treatment eect" (Spiegelhalter
et al., 2004), the result. Use of non-informative priors therefore allows the data
to `speak for itself' and the resulting posterior will have no subjective opinion
attached to it.
The frequentist approach allows calculations of 95% condence intervals, whilst
the Bayesian `equivalent' produces a 95% credibility interval. Any percent can
be used for these intervals, however the 95% is one of the most commonly used
and corresponds to the 5% signicance level. Whilst a 95% condence interval
will 95% of the time contain the true value of the parameter, the 95% credibility
interval has a 95% probability of the true estimate being contained within it. The
Bayesian credibility intervals are generally narrower due to the additional priorCHAPTER 1. INTRODUCTION 6
information, although this will probably depend upon the model being used.
In this thesis the parameters for the treatment eect and its variation have
both been given non-informative prior distributions to start with, before alterna-
tives to these non-informative priors are then considered. The recent development
of software for implementing the Bayesian approach allows these methods to be
used relatively easily. The package used for the Bayesian analysis in this thesis
is WinBUGS version 1.4.3 (2007), which uses Markov Chain Monte Carlo meth-
ods (MCMC), and packages in R version 2.6.1 (2007) have been used to allow
WinBUGS to run from within R.
The results obtained via Bayesian methods can be similar in a numerical sense
to those obtained using the frequentist methods, however there is the advantage
that the Bayesian method can account for prior subjective opinion and the result
is updated in light of the data.
1.4 Aims
The main aim of interest in this project is to determine appropriate models for
meta-analyses. In doing this, the initial question of whether there is a relationship
between the absolute treatment eect and the heterogeneity of a meta-analysis,
all other things being equal will be examined. If there is no treatment eect,
one would expect no variation between the studies; however no variation between
the studies does not necessarily imply no treatment eect. A large treatment
eect indicates there may be a lot of variation between studies, but there doesCHAPTER 1. INTRODUCTION 7
not have to be. If a relationship is seen to exist, the question of how this can be
incorporated into the meta-analysis will then be considered
Another area of interest for this thesis is to determine which variables can
feasibly be transferred between clinical trials. A meta-analysis is performed as
mentioned previously on clinical trials which are similar in the sense that they
look at the same new treatment, at the same concentration, and compare the
results of this new treatment to the results from a single current treatment or
placebo to determine whether or not this new treatment has a signicant eect.
This seems to be a reasonable comparison of results since each clinical trial which
will be included in the meta-analysis hopes to come to the same conclusion as
the remaining clinical trials. It does not appear reasonable to construct a meta-
analysis which allows the inclusion of various clinical trials which have considered
the dierence between dierent treatments, since the main aim of a meta-analysis
is to look at the treatment eect which can be transferred between the clinical
trials. One might be interested however, in determining whether or not it would
be reasonable to allow meta-analyses of clinical trials which consider dierent
treatments if the treatment eect was not transferable between clinical trials. In
this case, the meta-analyses could allow for the transfer of the variance.CHAPTER 1. INTRODUCTION 8
1.5 Thesis Overview
To allow the reader to obtain some background knowledge of where the data
for this thesis originated, Chapter 2 goes into some detail of what data are avail-
able and what it has already been used for, as well as a small literature review
regarding publications concerning both meta-analyses and Bayesian approaches
to meta-analyses.
Chapter 3 then looks more specically at the relationship between the treat-
ment eect and its variation, to determine whether these parameters should ide-
ally be modelled as individual parameters, or whether this is not feasible.
More indepth analysis of the meta-analyses will be computed using a Bayesian
analysis in Chapter 4, as well as the results from these analyses, before looking
at ideas for possible future work which will be in Chapter 5.Chapter 2
Meta-Analyses
2.1 Summary Estimates
As previously mentioned in Chapter 1, a meta-analysis produces one single
overall treatment eect estimate for a group of clinical trials. This estimate can
be measured using dierent metrics: the metric used depends on the type of data
available and the format.
Normally distributed data makes use of the continuous data: the absolute
dierence between the means,
^  =  yT    yC
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where  yT represents the mean for the treatment group, likewise for the control
group; the standardised dierence between the means,
^  =
 yT    yC
s
where s =
p
s2, s2 representing the unbiased estimate of 2 based on the usual
pooled sample variance, which will allow data from dierent scales to be com-
bined.
Survival data uses the log-hazard ratio as an estimate for the treatment dif-
ference,
 = log

hT(t)
hC(t)

;
where hTt and hCt represent the hazard functions for the treatment group and the
control group respectively, whilst the ordinal data makes use of two types of the
log-odds ratio as discussed in Whitehead (2002), one based on the proportional
odds model,
 = log

QkT(1   QkC)
QkC(1   QkT)

where  is the log-odds of the treatment group having a greater success than the
control group (QkT and QkC represent the cumulative probabilities of falling into
category k(k = 1;:::;m) or better for the treated and control groups respectivelyCHAPTER 2. META-ANALYSES 11
(Whitehead, 2002)), and the other based on the continuation ratio model,
 = log

hkT(1   hkC)
hkC(1   hkT)

with hkT =
pkT
1   Q(k 1)T
and hkC =
pkC
1   Q(k 1)C
.  produces a positive result
when the treatment group is better than the control group.
Binary data, which is the form of data used in this thesis, uses three main
metrics: the risk dierence,
 = pT   pC
the logarithm of the odds ratio,
 = log

pT(1   pC)
pC(1   pT)

and the logarithm of the relative risk,
 = log

pT
pC

The notation used here is the proportion of patients who had the event of interest
in the treatment group, pT, and the proportion of patients who had the event of
interest in the control group, pC, and the estimates can be obtained using the
Maximum Likelihood formulas.
The two metrics most commonly used for binary data are the risk dierence,CHAPTER 2. META-ANALYSES 12
and the natural logarithm of the odds ratio. The risk dierence values are re-
stricted to the interval [-1, 1], although \condence intervals based on asymptotic
theory can include points outside these limits" (Whitehead, 2002), whereas the
log-odds-ratios can take values anywhere between  1 and +1, resulting in the
log-odds-ratio generally being preferred. The log-odds-ratio is also known for its
stability across a range of studies. The log-odds-ratio is usually used instead
of the odds-ratio to allow the assumption of normality to be more reasonable
(Spiegelhalter et al., 2004).
The metric chosen depends greatly on the format of the data available. For
example, if the data provided is Binary and is given in the summary form of the
risk dierence, then one is restricted to using the risk dierence. If the data is
provided in summary statistic form, with the number of events and non-events,
there is more choice available, one could use any of the three mentioned met-
rics. The preference is to be able to produce a meta-analysis using the raw data,
allowing analysis at the individual patient level so questions on other factors,
for example, demographic issues may also be considered. This information is
not generally available however, with most researchers using data provided in
published papers of the trial results.
2.2 The Models
Once the data has been obtained and the decision upon which metric to use
has been considered, one will then consider whether to use a xed eects approachCHAPTER 2. META-ANALYSES 13
or a random eects approach. Assuming a xed eects model on a meta-analysis
which consists of k independent studies with an overall treatment estimate ,
and individual study treatment estimates Yi;i = 1;2;:::;k, E(Yi) =  and the
variance of the individual treatment estimates for each study i, Var(Yi) = 2
i,
allowing the xed eects model to be expressed as below.
Yi =  + i where i  N(0;2
i)
Yi  N(;2
i):
It is assumed here that 2
i are known and equal to ^ 2
i. Then let the weights, !i,
be the inverse variance of the summary statistic for each study i, !i = 1=(2
i).
The xed eects model may then be expressed as
Yi  N(;1=!i):
The overall treatment eect,  is estimated via an averaged treatment eect across
the k trials,
^  =
Pk
i=i ^ i!i
Pk
i=1 !i
: (2.1)
Consider now the random eects model which allows the incorporation of
heterogeneity into the previously stated xed eects model. The random eectsCHAPTER 2. META-ANALYSES 14
model unlike the xed eects model does not assume a common underlying treat-
ment eect, denoted  in the xed eects model. Instead, it allows the treatment
eect to dier between the studies.
Assuming once again a meta-analysis consists of k independent studies, with
Yi the individual study treatment estimates and ^ 2
i the variance of Yi;i =
1;2;:::;k. Letting i represent the true treatment eect for study i,
Yi = i + i where i  N(0; ^ 2
i)
i =  + "i where "i  N(0;2)
for i = 1;2;:::;k and the i and "i are assumed independent, allowing the random
eects model to be rewritten as
Yi = i + i + "i where Yi  N(; ^ 2
i + 2)
where the extra variance component here, 2 is a measure of the heterogeneity,
and  is the overall treatment eect. The weights, !i are again the inverse
variance of the summary statistic for each study i and incorporates the extra
variance component for the random eects variance, !i = 1=(2
i + 2). It is
noticeable from this notation, that should there be no heterogeneity present, 2
= 0, one will obtain the xed eects model.
An important aspect of producing a meta-analysis is to ensure the check forCHAPTER 2. META-ANALYSES 15
statistical heterogeneity between any trials is produced and accounted for, if nec-
essary, before using the results obtained. Some statisticians believe that should
heterogeneity be present in a meta-analysis a random eects model should be
used rather than a xed eects model to allow the combination of the individual
trials whilst accounting for the heterogeneity within the model. Not everyone is
of this opinion however, and some believe a xed eects model (which corrects
in some form for the heterogeneity) is still reasonable. Since heterogeneity can
(and often does) occur, regardless of which model has been used to produce the
meta-analysis, the heterogeneity has to be checked (and accounted for if present)
to prevent invalid results. Assuming one has checked for heterogeneity and it is
reasonable to discount this then a meta-analysis using a xed eects approach
seems feasible. If on the other hand, one performs a check for heterogeneity and
discovers that there is signicant heterogeneity in the meta-analysis, then this
must be either included in the model, perhaps by means of a random eects
model, or used to stratify the trials before producing overall treatment eect
estimates for each strata.
The results throughout this thesis have used the random eects model which
can take into account any heterogeneity that may be present, yet still return the
results that would be obtained from a xed eects model should there be no
heterogeneity.CHAPTER 2. META-ANALYSES 16
2.3 Bias
Publication bias, mentioned briey in Chapter 1, is one of the main sources
of bias which can occur when constructing a meta-analysis, but can be checked
for without too much diculty. Graphically, a funnel plot can be used to detect
publication bias, however there are also statistical methods which can be used
which are less subjective.
Figure 2.1. Funnel Plots for one of the Meta-Analyses with 34 trials
A funnel plot involves plotting the sample size of each of the individual trials
against the trials' estimated treatment eect size and analysing the shape of the
plot, however Whitehead (2002) makes note that instead of using the sample
size one can use the precision of the treatment eect (the inverse of the standard
error). Some examples of these funnel plots are displayed in gures 2.1 and 2.2. In
these gures, the circles represent each of the individual trials within each meta-
analysis, with the vertical black dashed line representing the overall xed eectsCHAPTER 2. META-ANALYSES 17
Figure 2.2. Funnel Plots for one of the Meta-Analyses with 6 trials
treatment estimate for the meta-analyses (using the Mantel-Haenszel method,
Mantel and Haenszel (1959)) and the vertical black solid line representing no
treatment eect. If there is no evidence of any publication bias, the plot should
resemble an upside down symmetric funnel, with a large variation in the observed
eect size being reasonable for trials with small sample sizes, and a gradually
reducing variation about the true eect size as the sample sizes of the trials
increases until the top of the plot displays very little variation about the true
eect size for trials with a large sample size. Figure 2.1 is a good example of a
funnel plot which indicates no evidence of any publication bias. In the event of
publication bias occurring, one would tend to notice very few studies within the
bottom right-hand corner, of the funnel plot, those which correspond to small
numbers of trials and high values for the log-odds ratios (those trials which show
a poor treatment eect). Figure 2.2 is the best example of this from the 125
meta-analyses considered in this thesis, however the assumption of no publicationCHAPTER 2. META-ANALYSES 18
bias for this specic meta-analysis based solely on the graph would be deemed
reasonable since there are only six trials within this meta-analysis.
2.4 Measures of Heterogeneity
Using a random eects model allows the incorporation of heterogeneity, the
between study variation, into the model. There are several ways in which to
measure the heterogeneity and some of these are described here.
One of the most widely used measures of heterogeneity in practice today uses
DerSimonian and Laird's method of moments (DerSimonian and Laird, 1986)
which can be found by equating the sample statistic for the heterogeneity, Q!,
with its expectation,
2
DL = max

0;

Q!   (k   1)

P
i !i  
(
P
i !2
i)
P
i !i


(2.2)
The k represents the number of trials in the meta-analysis and the !i's are the
weight assigned to triali. The test statistic for the heterogeneity, Q!, is calculated
using the formula
Q! =
P
i !i(yi    y!)2
Biggersta and Tweedie (1997) proposed a method of measuring the hetero-
geneity which is similar to the method of moments proposed by DerSimonian and
Laird (1986), yet allows the incorporation of the uncertainty when estimating theCHAPTER 2. META-ANALYSES 19
heterogeneity into the estimates for the treatment eect, it's standard error and
the condence intervals. Brockwell and Gordon (2007) compare these measures
of heterogeneity, along with the method using maximum likelihood estimators
outlined below, and note the similarities between DerSimonian and Laird (1986)
and Biggersta and Tweedie (1997)
\there is very little dierence between estimated coverages for the BT [Bigger-
sta and Tweedie (1997)] method and those of the DL [DerSimonian and Laird
(1986)] method...[and] the BT [Biggersta and Tweedie (1997)] method also re-
quires numeric routines to obtain condence intervals for ".
Brockwell and Gordon (2007) note also that both the methods based on the
method of moments (DerSimonian and Laird (1986) and Biggersta and Tweedie
(1997)) \estimated coverage probabilities are frequently well below the nominal
level of 0.95...particularly so when k is small", resulting in the condence inter-
vals being insuciently small.
Hardy and Thompson use a method based on the use of Maximum Likelihood
estimators (Hardy and Thompson, 1996), which uses an iterative procedure to
obtain the overall treatment eect ^  and the heterogeneity 2
HT,
2
HT = max

0;
Pk
i=1 !2
if(^ i   ^ )2   2
ig
Pk
i=1 !2
i

(2.3)
where !i =
1
2
i + 2
HT
and ^  =
Pk
i=1 !i^ i
Pk
i=1 !i
. Equation 2.3 is solved iteratively until
it converges.
The maximum likelihood methods are noted to \underestimate variances"CHAPTER 2. META-ANALYSES 20
(Thompson and Sharp, 1999) however, and so the method of restricted maxi-
mum likelihood (REML) estimates (Thompson and Sharp, 1999) are also used.
The REML estimator, like the maximum likelihood estimators, uses an iterative
procedure to obtain the same estimators ^  and 2
REML upon convergence using,
2
REML = max

0;
sumk
i=1!2
if(k=(k   1))(i   ^ )2   2
ig
Pk
i=1 !2
i
g (2.4)
again with !i =
1
2
i + 2
REML
and ^  =
Pk
i=1 !i^ i
Pk
i=1 !i
.
2.5 Background on the Data
2.5.1 Introduction
The data which has been used as the basis of this thesis is from a journal
article in the Statistics in Medicine journal, Engels et al. (2000), titled \Hetero-
geneity and statistical signicance in meta-analysis: an empirical study of 125
meta-analyses" and has been kindly provided by Christopher Schmid, one of the
authors.
This journal article studies the results of 125 individual meta-analyses, and
examines specically the heterogeneity in each of these meta-analyses and which
metric, or metrics, should be used to measure the treatment eect, focusing on
studies with binary outcomes. Engels et al. (2000) stated that it was \the largest
systematic examination of meta-analyses...to our knowledge", although other
similar studies on a smaller scale have been published (DerSimonian and Laird,CHAPTER 2. META-ANALYSES 21
1986; Berlin et al., 1989).
Engels et al. (2000) declare \there may be no metric that is `best' for all cir-
cumstances" and that the \conclusions drawn from a meta-analysis may depend
on which metric is used, especially when...heterogeneity is present".
The aim of the article was to answer three specic questions:
1. \How often are the collections of trials used in meta-analysis heteroge-
neous?"
2. \When do xed eects and random eects methods give dierent estimates
of treatment eect?"
3. \When does summarising risk dierences give a dierent impression of
treatment eect than summarising odds ratios?"
Journal Number of Meta-Analyses
Ann Intern Med 7
Arch Intern Med 2
BMJ 28
Circulation 6
CCPC 45
Drugs 1
JAMA 8
Lancet 14
New Engl J Med 12
Journal Not Specied 2
Table 2.1. Journals from which the selected Meta-Analyses originated
The meta-analyses which have been included were selected from two sources,
major medical journals which publish large numbers of meta-analyses and theCHAPTER 2. META-ANALYSES 22
1994 Cochrane Pregnancy and Childbirth database (CCPC). The medical jour-
nals which were used are Annals of Internal Medicine, Archives of Internal Medicine,
British Medical Journal, Circulation, Journal of the American Medical Associ-
ation, Lancet, and New England Journal of Medicine, all of which were limited
to the issues from years between 1990 and 1996. From the meta-analyses within
this search criteria, the ones which were chosen were randomized controlled trial
data with binary outcomes in the form of 2 x 2 tables.
Field Number of Meta-Analyses which
Focus on the specied Field
Cancer 17
Cardiovascular Disease 43
Diabetes 1
GI 6
Infectious Diseases 5
Neurology 1
Pediatrics 3
Perinatal 45
Psychiatry 4
Table 2.2. The Fields in which each of the Meta-Analyses primary focus oc-
curred
The CCPC is the single source which accounts for most of the meta-analyses,
45 of the 125 available as displayed in table 2.1, all of which contain meta-analysis
results for the same eld, perinatal. However, not all of these meta-analyses focus
on a single outcome, there are more than 20 dierent outcomes included across
the 125 meta-analyses, from low birth weight to respiratory distress syndrome to
mortality at various ages. The meta-analyses which come from the major medicalCHAPTER 2. META-ANALYSES 23
journals cover various dierent elds of medical interest, some of which include
cancer, myocardial infarction, cardiovascular disease and infectious diseases, as
well as varying outcomes and/or treatments within each of the elds of interest.
Table 2.2 highlights the main eld groups occurring in the 125 meta-analyses and
a count of how many meta-analyses focused on each eld.
2.5.2 Inclusion Criteria
The inclusion criteria used to obtain the meta-analyses required each of the
meta-analyses to have at least six clinical trials to ensure each contained su-
cient data which would result in a valid eect estimate. Table 2.3 displays some
information about the summary statistics of the clinical trials which are used
to obtain the 125 meta-analyses, which conrms that all of the meta-analyses
included at least 6 clinical trials, although the numbers of clinical trials does
dier greatly between meta-analyses, with the average meta-analysis containing
13 clinical trials.
It was also a requirement that each meta-analysis had at least one event in
the control arm, and that the average number of events in the trial control arms
be at least ve. Table 2.5 summarises the number of events in both treatment
arms, the treatment arm and the control arm. These summaries also conrm the
inclusion criteria specied by Engels et al. (2000) concerning the average num-
ber of events in the trial control arms is indeed ve. Assuming nT = nC, the
average number of patients in one treatment group for the 125 meta-analyses is
summarised in table 2.4. The mean number of patients in a treatment group isCHAPTER 2. META-ANALYSES 24
462, with the smallest average number of patients in a single treatment group
being 22.
If any trial had no events in either arm, a continuity correction, as used by
various authors, Yates (1934), Anscombe (1956), and Cox and Snell (1989), was
implemented: one half was added to each cell of the corresponding 2 x 2 table
before calculating the summary eect statistics. The same continuity correction
was also used when the number of events in any treatment arm in any given trial
equaled the total number of patients corresponding to that treatment in that
particular trial. Anscombe (1956) notes that by implementing this correction,
the \bias can be very nearly removed", whilst improving the distributional as-
sumption of Normality, Cox and Snell (1989). Very few trials contained zero, or
n, events in either arm due to the strict criteria pre-determined for the inclusion
of meta-analyses and so the authors were condent that this correction had very
little eect on the overall results.
Summary Statistics
Minimum 6
Median 10
Mean 13.06
Maximum 62
Table 2.3. Summary statistics for the
numbers of clinical trials included in
the 125 MA
Summary Statistics
Minimum 22.29
Median 129.77
Mean 461.82
Maximum 13744.12
Table 2.4. Summary statistics for
the average numbers of patients in one
treatment group for the 125 MA, as-
suming the numbers of patients in the
treatment and the control group are
equal
There is one inclusion criterion which has been stated by Engels et al. (2000)CHAPTER 2. META-ANALYSES 25
which does not appear to have been implemented: the exclusion of any trial with
fewer than ten subjects in either arm. Engels et al. (2000) stated in their inclu-
sion criteria \To avoid very small trials, we excluded from the meta-analysis any
trial with fewer than ten subjects in either arm". Of the 125 meta-analyses, 21
of them included at least one trial with less than ten subjects in either treatment
arm. These trials were removed and the summary statistics were then calculated.
However, upon checking the data with the summary statistics which were pro-
vided by the authors, the results calculated diered slightly from the summary
statistics which had been provided. It was then noticed that by not excluding
the very small trials (those with less than ten subjects in either arm), the results
appeared to match in almost all of the data (see Chapter 3 section 3.2).
Control Group Treatment Group
summary statistics summary statistics
Minimum 5.29 2.8
Median 22.91 19.33
Mean 43.89 39.42
Maximum 578.33 536
Table 2.5. Summary statistics for the average numbers of events in both the
control arm and the treatment arm for all 125 MA
2.5.3 Calculating the Summary Statistics
Since the data provided were in binary form, the metrics available are auto-
matically limited to the three main metrics previously specied for binary data:
the risk di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methods used of these three are the risk dierence and the log-odds-ratio, and as
mentioned previously, the log-odds ratio is generally accepted as a fair measure
of treatment eect due to its ease of transferability to the real line, therefore the
log-odds-ratio has been the main focus of the analysis throughout this thesis.
Using the previously specied general formula for the calculation of the treat-
ment eect estimates, 2.1, the summary estimates can be calculated for each met-
ric, with the weights corresponding to the formula for the random eects weight,
!
i = 1=(2
i + 2
i ), which can be rewritten as !
i = 1=((1=!i) + 2), where !i =
1=2
i, with the xed eects estimates using the same formulae when 2 = 0.
The xed eects weights are calculated as follows,
!LORi =
1
1
nTipTi(1   pTi)
+
1
nCipCi(1   pCi)
for the logarithm of the odds ratios
!LRRi =
1
(1   pTi)
nTipTi
+
(1   pCi)
nCipCi
for the logarithm of the relative risks
!RDi =
1
pTi(1   pTi)
nTi
+
pCi(1   pCi)
nCi
for the risk dierences
2.5.4 Results
Engels et al. (2000) examine both the odds ratio and the risk dierence met-
rics, for both the xed eects model and the random eects model to attempt to
provide a possible preference, and to determine whether the two metrics produce
the same results as one would hope. The value used for the heterogeneity is theCHAPTER 2. META-ANALYSES 27
one-tailed p-value for the calculated Q-statistic. The risk dierence would be
classed as being more heterogeneous than the odds ratio if \if the p-value for the
risk dierence Q-statistic is less than the p-value for the odds ratio Q-statistic"
and a meta-analysis would be termed \`heterogeneous' when the corresponding
Q-statistic p-value is below a nominal cut-o, usually 0.05 or 0.10".
The heterogeneity among the two metrics were compared and it was noted
that \the risk dierences usually displayed more heterogeneity than the odds ra-
tios", with the risk dierences either \more heterogeneous than the odds ratios"
or \the risk dierences were judged heterogeneous when the odds ratios were not".
There were a small number of cases (three) which noted \the odds ratios hetero-
geneous when the risk dierences were not". Engels et al. (2000) noted however,
that these results appeared to contradict results from two previous studies which
reported \similar heterogeneity measures for risk dierences and odds ratios",
yet Engels et al. (2000) indicated the conicting results could be due to a lack
of \sucient power to detect dierences in heterogeneity between risk dierences
and odds ratios" since the number of meta-analyses used in each of the other
studies were smaller, nine (DerSimonian and Laird, 1986) and 22 (Berlin et al.,
1989). Engels et al. (2000) also note another couple of reasons, including the
sample may not be a good \representative of meta-analyses found in clinical re-
search" and the small number of studies within the meta-analyses \(Berlin et al.,
1989) included nine meta-analyses with fewer than six trials, meta-analyses that
(Engels et al., 2000) would have excluded".
Engels et al. (2000) were interested in determining whether the results of aCHAPTER 2. META-ANALYSES 28
meta-analysis were dependant on the metric chosen to produce the summary es-
timates. The summary estimates for each meta-analysis using the two dierent
metrics were compared and there were no cases reported of the metrics being sig-
nicant in opposite directions, allowing one to conclude the results \from meta-
analyses are robust to changes of metric". Engels et al. (2000) then go on to
examine dierent levels of signicance for the dierent summary estimates (both
xed eects and random eects) for two-sided p-values, noting \that random ef-
fects estimates were often less signicant than xed eects estimates".
The meta-analyses were then split into four subgroups;
 \`Homogeneous'...in which neither the odds ratios nor the risk dierences
were heterogeneous"
 \Meta-analyses in which both risk dierences and odds ratios were hetero-
geneous"
 \Meta-analyses in which only the risk dierences were heterogeneous"
 \Meta-analyses in which only the odds ratios were heterogeneous"
with the denition of heterogeneous being \a Q-statistic p-value less than 0.10".
The majority of the meta-analyses fell into the `homogeneous' subgroup (50.4
percent), with 32.8 percent of the meta-analyses having both metrics heteroge-
neous, 14.4 percent heterogeneous for just the risk dierences and the remaining
2.4 percent heterogeneous for just the odds ratios.
The random eects summary estimates and standard errors allow for the extra
heterogeneity parameter which the xed eects estimates do not and so will leadCHAPTER 2. META-ANALYSES 29
to dierent values when heterogeneity is present. Engels et al. (2000) noted the
calculated estimates did not dier greatly between the xed eect approach and
the random eect approach, however the standard errors of the random eects
estimates were greater than those of the xed eects estimates and \the overall
eect of heterogeneity was to make most random eects estimates less signicant
than the corresponding xed eects estimates, for both the odds ratio and risk
dierence metrics".
The xed eects estimates for the odds ratios and the risk dierences \pro-
vided similar levels of signicance" for the meta-analyses which were classed as
`homogeneous'. The same conclusion was declared for the random eects esti-
mates for the meta-analyses in which both the risk dierences and the odds ratios
were heterogeneous, indicating \the choice of metric used to measure and sum-
marize the treatment eect is not crucial", however Engels et al. (2000) state \the
risk dierence may not be the most appropriate metric to use in meta-analysis,
because risk dierences may be substantially heterogeneous among trials [and]
the risk dierence metric tends to give greatest weight to trials with low event
rates...[although] trials with low event rates would seem to oer little infor-
mation about treatment eects". Engels et al. (2000) also state their results
\suggest that the odds ratio is more likely than the risk dierence to remain
constant across populations" and so this should be incorporated if an absolute
measure of treatment eect is required.Chapter 3
Examining the Relationship
3.1 Introduction
One of the main aims of this thesis is to determine whether the treatment
eect estimates and their corresponding heterogeneity values are independent,
or if some sort of relationship exists (Senn, 2007b). These two measures are
often modelled as independent, however it is of interest to determine whether
this is actually the case, or whether the heterogeneity varies with the absolute
size of the treatment eect estimate. One might presume a meta-analysis with no
treatment eect should indicate no heterogeneity, whilst a meta-analysis with a
large absolute treatment eect could indicate anywhere between no heterogeneity
and lots of heterogeneity.
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3.2 Checking the Data
The rst focus of interest is to produce a quality control study which ensures
the statistics provided by Engels et al. (2000) coincide with those reproduced. As
previously mentioned, the data provided were in binary form, and although the
metric focused on is the log-odds-ratio, the checking of the values provided for
the random eect mean estimate and its standard error were computed for each
of the three metric choices available. This is to ensure the results obtained are
consistent with those provided by the authors. After implementing the continu-
ity correction, the random eect mean estimates and their standard deviations
for each metric were calculated for each of the 125 meta-analyses in turn using
scripts within R version 2.6.1. These computed values were then compared to
the values in the data set which were provided.
As previously noted in Chapter 2 section 2 (Background on the Data), im-
plementing one of the stated exclusions, removing any trials with fewer than ten
subjects in either arm, caused deviations from the values for all the meta-analyses
which this criteria aected. By ignoring this exclusion criteria, the values calcu-
lated matched almost exactly those provided, indicating that this specic criteria
had not been implemented, although the dierences are minimal and should not
aect any results Engels et al. (2000) produced. Since the original values pro-
vided were calculated with this criteria not being implemented, the criteria has
not been implemented for this thesis either.
The random e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using a modication of the method used by DerSimonian and Laird (1986), as
used by Fleiss and Gross (1991). The results provided by Engels et al. (2000)
are actually provided for the odds ratios and so the exponential of the calculated
log-odds-ratios are compared with the odds ratio estimates provided.
Figure 3.1. Plots comparing the calculated and given values for the odds-ratio
summary estimates and the corresponding standard deviations of the odds-ratio
summary estimates.
Of the 125 meta-analyses, there were only two discrepancies which occurred
between the results from the quality control study and the data which was pro-
vided: one for the odds-ratio estimate, the data provided had an estimate for the
odds-ratio of 0.177645, whilst the quality control estimate provided an odds-ratioCHAPTER 3. EXAMINING THE RELATIONSHIP 33
estimate of 5.6292; and the other discrepancy occurred for the standard deviation
of the odds-ratio estimate, the data provided had an estimate for the standard
deviation of 0.542, whilst the quality control estimate provided a standard devia-
tion value of 0.0542. The exponential of the calculated log-odds ratios (and their
corresponding standard deviations) are also compared graphically against those
provided by Engels et al. (2000), Figure 3.1.
In the standard deviation instance, it appears the discrepancy is the result
of an input error for that particular result, however at rst glance, it remains
unclear whether this is also the case for the dierent estimate values for the
odds-ratio. Taking the natural logarithm of the value provided by Engels et al.
(2000) (0.177645) produces a log-odds ratio value of -1.727968, whilst the com-
puted log-odds ratio in the quality control study is 1.727975, indicating an input
error in the results provided by Engels et al. (2000).
Examining the computed statistics for the risk dierence metric, there are
several more discrepancies (52 of the 125 meta-analyses contained discrepancies).
The majority of these discrepancies occurred for both the risk dierence value
and it's standard error (40 of the 52 meta-analyses), however there are some cases
in which only one of the calculated values, either the risk dierence (10 of the
52 meta-analyses) or the standard error disagrees (2 of the 52 meta-analyses).
Most of these appear on rst inspection to be the result of either rounding error
or input error since the values provided do not dier greatly from the values
calculated. However, after a closer look at the results, it appears that some of the
risk dierence treatment estimates and their corresponding standard deviations,CHAPTER 3. EXAMINING THE RELATIONSHIP 34
which were provided, have been calculated without implementing the continuity
correction to adjust for cases in which the number of events is equal to either
zero or the number of patients in the corresponding treatment group. In fact, in
all except two of the meta-analyses which included trials containing either zero
or n events, the continuity correction had not been used.
Figure 3.2. Plots comparing the calculated and given values for the risk dier-
ence summary estimates and the corresponding standard deviations of the risk
dierence summary estimates.
Ignoring the continuity correction, the majority of the results which did not
previously match the values provided, now match exactly (60% of the 52 meta-
analyses). The majority of the remaining meta-analyses which do not match theCHAPTER 3. EXAMINING THE RELATIONSHIP 35
results exactly after ignoring the continuity correction are similar in magnitude,
implying the discrepancies may be due to a rounding error somewhere in the
calculations.
The two meta-analyses for which the continuity correction had been applied
produce results which disagree from those provided if the continuity correction is
ignored. The results for the meta-analyses which had no trials with either zero or
n events remain unchanged since the data for these meta-analyses has not been
altered.
Plots comparing the calculated risk dierence estimates (and their standard
deviations) with those provided by Engels et al. (2000) are also produced here
after the continuity correction has been implemented, Figure 3.2.
Lastly, checking the relative risk (rather than the log-relative risk) values pro-
vided by Engels et al. (2000), all 125 relative risk values and their corresponding
standard error (s.e.i =
p
1=!
i for i = 1;:::125) match to four decimal places
after implementing the continuity correction.
The inclusion criteria stated appeared reasonable. To ensure the possibility of
invalid eect estimates has been reduced, all meta-analyses with very few trials
(less than six) were excluded, and only meta-analyses with an average of ve
events in the trial control arms were included.CHAPTER 3. EXAMINING THE RELATIONSHIP 36
3.3 Exploratory Analysis of a Relationship
An immediate reaction to examining the results of a meta-analysis is to auto-
matically focus solely on the eect of the treatment. Perhaps one should not be
interested in this alone, but interested in whether or not there is a relationship
between the eect of the treatment and the heterogeneity. It might be of interest,
for example, to attempt to determine whether meta-analyses which have a larger
treatment eect coincide with larger between study variation.
Figure 3.3 shows the relationship between the treatment eect estimates and
the heterogeneity for each of the three metrics considered. The heterogeneity in
these graphs is estimated using the ratio Q/degrees of freedom, the same ratio as
used by Hardy and Thompson (1998) in one of their practical examples, with Q
corresponding to the Q-statistic calculated for each random eects metric respec-
tively, and the treatment eect is taken as the absolute value of the treatment
eect estimates, thus ignoring the direction of the treatment eect estimates.
These graphs clearly indicate there is some positive relationship between the
treatment eect and the heterogeneity for all three metrics, with the correspond-
ing correlation values provided in Table 3.1. Each of the correlations provided
in Table 3.1 are highly signicant with p-values produced for each correlation of
<0.0001.
Signicant positive correlations for each metric conrm that regardless of the
metric chosen, and all other things equal, there does appear to be a signicantCHAPTER 3. EXAMINING THE RELATIONSHIP 37
Figure 3.3. Plots showing the between study variation against the treatment
eect for all three metrics: the relative risk; the risk dierence; and the log-odds-
ratio.CHAPTER 3. EXAMINING THE RELATIONSHIP 38
Treatment Eect
Relative Risk Risk Dierence Log-Odds-Ratio
Random Eects Relative Risk 0.4238 - -
Between-study Risk Dierence - 0.3524 -
Variation Odds Ratio - - 0.4194
Table 3.1. Correlations for the treatment eect estimates and their respective
heterogeneity for each metric
relationship between the absolute treatment eect and the heterogeneity. As an-
ticipated, the meta-analyses for which the estimated treatment eect was not
signicant also indicate very little, if any, variation between studies. The high
between study variation (indicated by increasing values on the y-axis) arises in
meta-analyses with a signicant treatment eect (indicated by increasing values
on the x-axis).
Existing articles on meta-analysis assume the treatment eect and the het-
erogeneity are independent, but the apparent relationship occurring between the
two measures now causes some doubt about whether these previous analyses are
correct, and indeed if they are not how best it would be to tackle this possible
problem.
One author has already questioned the relationship between the treatment
eect estimates and their heterogeneity (Senn (2007b), Senn (2008)) and oered
a possible way to incorporate this relationship into the model. This will be con-
sidered later on in this thesis.CHAPTER 3. EXAMINING THE RELATIONSHIP 39
3.4 Summary
Upon examination of whether or not there is a relationship present between
the absolute treatment eect estimates in a meta-analysis and their correspond-
ing heterogeneity values, scatterplots indicated a possible positive relationship
between these two measurements for each of the three metrics available for mea-
suring binary data. Correlations produced for the relative risk, log-odds ratio and
risk dierence were 0.4238, 0.4194 and 0.3524 respectively and all were highly sig-
nicant at the 5% signicance level, with p-values of less than 0.001 produced for
each of the correlations.Chapter 4
Fitting a Bayesian Model
4.1 Introduction
Up to this point, a frequentist model which uses a Normal Normal model
based on summary statistics has been used. It is of interest now to consider a
Bayesian approach, which commonly uses one of two types of model, a Binomial
Normal model, or less frequently a Normal Normal model. Both of these Bayesian
models will be considered in this thesis.
As stated earlier, a Bayesian model treats the treatment estimate and the
heterogeneity, the two main areas of interest here, as random variables rather
than as xed single estimates. All of the unknown random variables are modeled
using priors.
For the moment, we will assume that there is no apparent prior information
on any of the unknown random variables and so it is desirable to model these
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priors as non-informative, allowing the data to speak for itself rather than at-
tempting to inuence the behaviour of the variables using informative priors.
Various non-informative priors are available, yet whether they are actually
non-informative or not is still debatable. Lambert et al. (2005) wrote a paper on
13 non-informative priors and the results produced by them in a simulation study
to determine how `non-informative' these so called priors actually were. Lambert
et al. (2005) noted the results produced by the priors which were believed to be
non-informative were not necessarily so, with some priors performing \particu-
larly poorly"and recommended a \sensitivity analysis", be performed to ensure
feasible results are produced.
4.2 Creating a Model
Starting with the more commonly used Binomial Normal model and focusing
on the log-odds-ratio, the following model, model 4.1, is constructed for the data
available.
The notation used in model 4.1 demonstrates the number of events ri for each
triali for the control group (c) and the treatment group (t) follow independent
binomial distributions with parameters pi, the proportion of events for triali and
ni, the number of patients in triali, for each treatment group respectively.
Using the linear logistic model, the proportion of events in the control group
for each triali is equal to  i, the overall eect for the control group for each triali,
whilst the proportion of events in the treatment group for each triali is set equal toCHAPTER 4. FITTING A BAYESIAN MODEL 42
 i plus i, i here representing the treatment eect for triali. Implementing the
logit scale improves the normal approximation of the likelihood (Spiegelhalter
et al., 2004). Note that model 4.1 can be written with an intercept instead,
however this would require also implementing a constraint on the  i's, to ensure
the coecient matrix is of full rank, for example setting  1 = 0.
rci  Bin(nci;pci)
rti  Bin(nti;pti)
logit(pci) =  i
logit(pti) =  i + i (4.1)
i  N(;2)
 i  N(0;1000000)
  N(0;1000000)
2  Inv   Gamma(0:1;0:1)
The treatment eect, i for each triali is the main focus of interest and is
given a normal prior with parameters , the overall treatment eect, and 2, the
variance of the treatment eect (the heterogeneity). The overall eect for each
triali,  i, and the hyperparameters,  and 2, are all given non-informative at
priors over a range large enough to include all possible values, which allows the
data to speak for itself since there is no prior knowledge for these parameters.
Non-informative priors on the  i's are implemented since the main interest hereCHAPTER 4. FITTING A BAYESIAN MODEL 43
lies on the treatment eect, i, however hyperparameters can be used to dene
the  i's.
Figure 4.1. Graphical model for random eects meta-analysis using the Bino-
mial model, model 4.1
One can construct a graphical model for model 4.1 as used by Whittaker
(1990), Figure 4.1.
The nodes in Figure 4.1 represent the parameters of the model and the data.
Single rectangles represent the observed variables (rCi, rTi), double rectangles
represent constants xed by the design of the study (nCi, nTi) and circles repre-
sent the unobserved parameters (pCi, pTi,  i, i, , 2). The arrows are drawn
from the parental nodes to descendant nodes and indicate the models conditional
independence assumptions, with the black line indicating stochastic dependence
and the red line indicating a logical function (Smith et al., 1995). In Figure 4.1,
the treatment eect (i) is conditionally independent of the trial eect ( i), given
 and 2.CHAPTER 4. FITTING A BAYESIAN MODEL 44
4.3 Published Data Check
4.3.1 Introduction
After having constructed the Bayesian model within WinBUGS, the rst step
was to check the model was working adequately, by using model 4.1 with data
that has previously been published, allowing the comparison of the results from
model 4.1 with the published results. Assuming the constructed model is working
properly, the results produced should match the published results.
For this check, the published data used were obtained from an example on
the selective decontamination of the digestive tract for patients in intensive care
units (Abrams and Sans o, 1998), which have been used previously for a couple
of meta-analyses (Digestive Tract Trialists' Collaborative Group (1993), Smith
et al. (1995)).
Abrams and Sans o (1998) examine the data which consist of 22 randomised
trials in binary form. Each trial has one treatment group and one control group,
with the number of patients with a respiratory tract infection and the total num-
ber of patients in each group recorded. Initially, the data have been analysed using
a xed eects model (Digestive Tract Trialists' Collaborative Group, 1993), how-
ever previous authors (Smith et al., 1995) noted a degree of heterogeneity in the
data, implying the random eects model should perhaps appear more reasonably
justied. Abrams and Sans o (1998) agreed with the random eects approach to
modeling this data and produced a signicant 2 statistic of 58.0 on 21 degrees
of freedom (p < 0.0001) for testing the null hypothesis of no heterogeneity, andCHAPTER 4. FITTING A BAYESIAN MODEL 45
so examined the data using a random eects model and focusing on the Bayesian
analysis.
Study Treated Control Odds Ratio
Infections Total Infections Total
1 7 47 25 54 0.20
2 4 38 24 41 0.08
3 20 96 37 95 0.41
4 1 14 11 17 0.04
5 10 48 26 49 0.23
6 2 101 13 84 0.11
7 12 161 39 170 0.28
8 1 28 29 60 0.04
9 1 19 9 20 0.07
10 22 49 44 47 0.06
11 25 162 30 160 0.79
12 31 200 40 185 0.66
13 9 39 10 41 0.93
14 22 193 40 185 0.47
15 0 45 4 46 0.10
16 31 131 60 140 0.41
17 4 75 12 75 0.30
18 31 220 42 225 0.71
19 7 55 26 57 0.17
20 3 91 17 92 0.15
21 14 25 23 23 0.03
22 3 65 6 68 0.50
Pooled 0.36
Table 4.1. Respiratory tract infections of 22 studies in the control and treatment
groups with individual and pooled estimates of odds ratios using the Mantel-
Haenszel method (Mantel and Haenszel, 1959)
Abrams and Sans o (1998) include a Table displaying the original data in
Binary format, also provided here in Table 4.1. Abrams and Sans o (1998) also
included in their table the summarised individual odds ratio estimates, and soCHAPTER 4. FITTING A BAYESIAN MODEL 46
the calculated odds ratio estimates are also contained in Table 4.1. Smith et al.
(1995) produced a similar table also, however it is interesting to note that despite
both Abrams and Sans o (1998) and Smith et al. (1995) using the same data in the
same format, their calculations for the odds ratio estimates dier for 15 of the 22
studies. Smith et al. (1995) make a note of which method was used to calculate
the odds ratios (the Mantel-Haenszel-Peto method), which one can reproduce
(the calculations for this method are provided in Yusuf et al. (1985) and compare
the observed number of deaths among the treated patients with the expected
number of deaths), whilst Abrams and Sans o (1998) have \Odds Ratios T/C" as
the title above the column containing the individual odds ratio values, which one
would presume indicates their calculated odds ratios are obtained by dividing the
treatment group by the control group. Further on in their paper, Abrams and
Sans o (1998) note the use of the value ni, where ni is the number of patients in
the treatment or the control group which are assumed to be equal, and in the
case of nTi 6= nCi an alternative is chosen, for example the average, the minimum,
or the maximum of nTi and nCi.
yi = log
pTi(1   pCi)
pCi(1   pTi)
with pTi =
rTi
nTi
; pCi =
rCi
nCi
(4.2)
yi = log
pTi(1   pCi)
pCi(1   pTi)
with pTi =
rTi
ni
; pCi =
rCi
ni
; ni = nTi + nCi (4.3)
yi = log
pTi
pCi
with pTi =
rTi
nTi
; pCi =
rCi
nCi
(4.4)
yi = log
pTi
pCi
with pTi =
rTi
ni
; pCi =
rCi
ni
; ni = nTi + nCi (4.5)
Unfortunately, however, I could not reproduce the values obtained by AbramsCHAPTER 4. FITTING A BAYESIAN MODEL 47
and Sans o (1998) for the individual odds ratios of the 22 studies. The values for
the individual odds ratios do not correspond to those obtained by Smith et al.
(1995), indicating the Mantel-Haenszel-Peto method has not been used. Dierent
formulas to calculate the individual log-odds-ratios were implemented (equations
4.2, 4.3, 4.4 and 4.5) with none of them reproducing the results obtained by
Abrams and Sans o (1998) exactly.
4.3.2 The Model Used
The model Abrams and Sans o (1998) used is slightly dierent to model 4.1.
Abrams and Sans o (1998) use a random eects model, as displayed in model
4.6 with yi corresponding to the summarised logarithm of the odds ratios, which
are assumed to have normal distributions, rather than allowing the raw data to
come from Binomial distributions. This is the Normal Normal model mentioned
previously rather than the Binomial Normal model already stated.
yi  N(i;2
i=ni) (4.6)
i  N(;2) i = 1;:::;k
In model 4.6, ni is the number of patients in either group, assuming the
number in each group is equal, and
2
i =
1
pCi(1   pCi)
+
1
pTi(1   pTi)
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where pCi and pTi correspond to the proportion of events in the control group
and the treatment group in triali (pCi and pTi are calculated using a common ni).
If the number of patients in each group is not equal, several choices for ni can
be made instead: an average, the minimum, or the maximum number of patients
in the treatment group and the control group, from i = 1, 2, :::, k. For this
specic meta-analysis, the numbers of patients were not equal across the groups
and therefore the average number of patients were used.
Using this Normal-Normal model within WinBUGS to obtain the Bayesian
results should produce very similar results to the frequentist calculations which
also assume a Normal-Normal model.
Model 4.6 can be rewritten as
yi  N(i;2
i)
i  N(;2) i = 1;:::;k
with 2
i =
1
rti
+
1
ni   rti
+
1
rci
+
1
ni   rci
(4.8)
after some simple rearrangement, where ni is the average number of patients in
trial i, i = 1, 2, :::, k.
The priors used by Abrams and Sans o (1998) for  and 2 were non-informative
Uniform(-10, 10) and Inverse-Gamma(3, 1) priors respectively. An Inverse-Gamma(0,
2) prior for 2 was also implemented, presumably to demonstrate some of the re-
sults of the sensitivity analysis produced.
This Normal Normal model can be written in the Bayesian format with theCHAPTER 4. FITTING A BAYESIAN MODEL 49
priors, as has previously been done for the Binomial Normal model (model 4.1)
and is displayed in model 4.9.
yi  N(i;2
i)
i  N(;2) i = 1;:::;k (4.9)
  Unif( 10;10)
2  Inv   Gamma(3;1)
where 2
i =
1
rti
+
1
ni   rti
+
1
rci
+
1
ni   rci
4.3.3 Looking at the Results
The results displayed in Table 4.2 include: the results obtained by Abrams
and Sans o (1998) for the priors previously stated; the results one obtains by
reproducing the published results using the same model, data and priors (with
a burn in of 5000 and a further 25,000 iterations); the results one obtains using
just a dierent vague prior for  (  N(0.0, 1,000,000)); the results one obtains
using just a dierent prior for 2 (  Unif(0, 10)); and the results one obtains
using the dierent priors for  and 2 together. Further vague priors were also
used to ensure the sensitivity analysis results are suitable, however these are not
displayed here.
The reproduced results in Table 4.2 for the expected values of the treatment
eect estimate () and the heterogeneity (2) are notably dierent to the resultsCHAPTER 4. FITTING A BAYESIAN MODEL 50
Parameter Result in Reproduced Result using Result using Result using
published result a dierent a dierent dierent vague
data vague prior vague prior priors for 
for  for 2 and 2 together
E() -1.488 -1.254 -1.256 -1.281 -1.281
SD() 0.230 0.1908 0.1915 0.2148 0.2143
E(2) 1.090 0.4346 0.4381 0.5801 0.5738
SD(2) 0.375 0.1937 0.1966 0.3347 0.3418
Table 4.2. Results for the published Bayesian analysis for model 4.6
published in Abrams and Sans o (1998). The expected value for the treatment
eect estimate in Abrams and Sans o (1998) is -1.488, with an expected value
of 1.090 for the heterogeneity, whereas the reproduced results using the same
priors and data are -1.254 for the treatment eect estimate and 0.4346 for the
heterogeneity. The sensitivity results for the model to reproduce the treatment
eect estimate and the heterogeneity are quite consistent with the reproduced
values, indicating the priors are non-informative and the results come from the
data itself, however the underlying reason for the results not matching those
published still has to be determined.
Upon further examination into the discrepancies, it appears similar results
can be obtained (again using the same priors and the same data) if a slightly
dierent formula for 2
i (equation 4.10) is used.
2
i = 1=pCi(1   pCi) + 1=pTi(1   pTi); (4.10)
Equation 4.10 looks similar to the equation used previously (equation 4.7),CHAPTER 4. FITTING A BAYESIAN MODEL 51
however typing equation 4.10 into R exactly as it is written fails to give the
expected result, that obtained via equation 4.7. This is due to the lack of brackets
in equation 4.10 which determine the correct ordering of the elements of the
equation.
Parameter Result in Reproduced Result using Result using Result using
published result a dierent a dierent dierent vague
data vague prior vague prior priors for 
for  for 2 and 2 together
E() -1.488 -1.428 -1.453 -1.446 -1.439
SD() 0.230 0.2118 0.215 0.245 0.2364
E(2) 1.090 07612 0.7528 1.018 1.021
SD(2) 0.375 0.2697 0.248 0.4105 0.415
Table 4.3. Results for the published Bayesian analysis for model 4.6 using
equation 4.10
The expected treatment eect estimate and heterogeneity are again calculated
as before with the only dierence being the change of equation, from equation
4.7 to equation 4.10. The results are displayed in Table 4.3. One can clearly
see from these results that the estimates produced for the treatment eect and
the heterogeneity match the results published by Abrams and Sans o (1998) more
than the previous results obtained using equation 4.7 for the calculation of the
2
i's.
4.4 Comparing Variances
As previously mentioned, upon attempting to reproduce the results obtained
by Abrams and Sans o (1998) for their Bayesian Normal-Normal model, there wereCHAPTER 4. FITTING A BAYESIAN MODEL 52
some conicting results. The reproduced overall treatment eect estimate was
quite a bit smaller than the one obtained by Abrams and Sans o (1998) (Table
4.2), as was the heterogeneity estimate. It was then discovered that altering
the formula for the 2
i's slightly by using equation 4.10 instead of equation 4.7,
resulted in values for the treatment eect estimate and the heterogeneity which
were closer to those produced by Abrams and Sans o (1998). This formula for the
2
i's however, cannot be rearranged into the usual variance formula,
2
i =
1
rti
+
1
nti   rti
+
1
rci
+
1
nci   rci
Figure 4.2. Comparing the variances calculated using Abrams and Sans o (1998)
formula for the variances and the common formula for the variances.
*The variances calculated using the formula in Abrams and Sans o (1998)CHAPTER 4. FITTING A BAYESIAN MODEL 53
Plotting the variances which have been calculated using the equation in Abrams
and Sans o (1998) against the variances calculated using the usual formula for the
variances (equation 4.7) and inserting a line of equality, one can see from the
graph (Figure 4.2) that there is a notable dierence between the two equations,
with the variance estimates calculated using the usual equation being larger in
magnitude.
Some of the estimates calculated using the equation in Abrams and Sans o
(1998) correspond fairly well with those obtained using equation 4.7, however
some estimates dier quite noticeably.
4.5 Bayesian and Frequentist Heterogeneity
4.5.1 Introduction
Having tted two Bayesian models to the data, a Binomial-Normal model,
model 4.1 and a Normal-Normal model, model 4.9, it will be of interest to examine
the results produced via the frequentist methods and the results produced via
the Bayesian methods to determine which dierences occur, if any. It seems
reasonable to compare the Bayesian and the frequentist methods individually
using both the Normal-Normal model and the Binomial-Normal model.
4.5.2 The Binomial-Normal Model
All of the Bayesian results, a sample of which are displayed in Table 4.4,
used a burn in of 5,000 and then a further 25,000 iterations for each of the twoCHAPTER 4. FITTING A BAYESIAN MODEL 54
Markov chains. Two Markov chains were used to check visually that convergence
of each parameter did not produce any unexpected problems. The frequentist
values for the random eects between study variation, also displayed in Table 4.4
are calculated using a nlmixed macro in SAS which incorporates the Binomial
Normal design used for the Bayesian model. The Bayesian results are obtained
using 4.1.
Data No. of Average no. Bayesian Bayesian Frequentist 95% C. I.
No. Clinical of patients Mean of S.D. of value for the for Bayesian
Trials in each Variation Variation between-study Estimate
trial variation of variation
23 51 311 0.01192 0.01782 0 (0.00052, 0.06346)
116 34 610 0.02528 0.03107 0 (0.00082, 0.1109)
123 42 356 0.00746 0.007848 0 (0.00057, 0.02859 )
79 23 87 0.2243 0.1463 0.0843 (0.02736, 0.588)
86 41 22 2.452 0.8812 1.4639 (1.178, 4.541)
115 62 49 0.121 0.06577 0 (0.03534, 0.2876)
26 6 1093 0.01317 0.02799 0 (0.00053, 0.07176)
70 6 616 0.6199 1.228 0.1750 (0.04376, 3.059)
74 6 6082 0.0374 0.0704 0.0072 (0.00133, 0.184)
41 6 68 1.157 1.566 0.4896 (0.159, 4.569)
107 6 61 0.04834 0.1635 0 (0.00066, 0.3164)
113 6 64 3.996 5.363 1.4226 (0.4144, 16.59)
Table 4.4. Comparing the frequentist and Bayesian methods for the heterogene-
ity (using model 4.1), with groupings to emphasise both the number of trials in
each Meta-analysis and the average number of patients within each trial
The results produced in table 4.4 for meta-analyses which have a large number
of trials as well as a large number of patients within each trial on average (theCHAPTER 4. FITTING A BAYESIAN MODEL 55
rst three rows of results) indicate the method used to calculate the frequentist
heterogeneity values seems to provide a fairly accurate estimate for the hetero-
geneity, with the results corresponding fairly well to the Bayesian heterogene-
ity results produced for the meta-analyses using WinBUGS. Both the Bayesian
method and the frequentist method produce a value close to zero for these three
meta-analyses.
There are however some dierences in the estimates for the frequentist ap-
proach and the Bayesian approach when the number of trials is fairly large and
the number of patients in each trial is quite small on average which one would
not expect. For example, data number 86 which has 41 clinical trials with an
average of 22 patients in each trial has a produced frequentist estimate for the
heterogeneity of 1.4639 whilst the Bayesian estimate is quite a bit higher (2.452),
although the frequentist estimate is still contained within the 95% Condence
Interval for the Bayesian heterogeneity (1.178, 4.541). For meta-analyses with
large numbers of trials, one would generally expect the frequentist value for the
heterogeneity to produce similar results to those obtained computing the hetero-
geneity via Bayesian methods. There are also dierences between the Bayesian
and the frequentist heterogeneity estimates when the number of trials is small,
although all of the frequentist estimates, apart from those which are calculated as
zero exactly, are included in the corresponding Bayesian heterogeneity condence
intervals.
One can note however, that all of the Bayesian results are slightly higher than
the frequentist results and the greater the frequentist heterogeneity result, theCHAPTER 4. FITTING A BAYESIAN MODEL 56
greater the dierence between the heterogeneity estimates.
The Bayesian results for the treatment eect estimates and the heterogeneity
using the Binomial-Normal model (model 4.1) can now be examined graphically
against the corresponding values obtained via the frequentist method, Figure 4.3,
providing some indication as to whether the results do coincide as one believes
they should. Assuming the results agree exactly, one would anticipate the points
to lie on the line of equality, the dashed line on both of the plots. Both plots use
the number of studies as the grouping variable, with the legend for the labelling
of the groups beside Figure 4.3.
Examining Figure 4.3, it appears the Bayesian method and the frequentist
method correspond well using the Binomial-Normal model to calculate the treat-
ment eect estimates with all of the estimates lying nearly perfectly along the
line of equality. Producing a linear regression results in a slope parameter of 1.01
with an intercept close to zero, -0.0112.
The Bayesian heterogeneity estimates for the Binomial Normal model how-
ever do not correspond as well to the frequentist heterogeneity estimates using
the nlmixed macro in SAS for the Bayesian Normal model, with hardly any of the
estimates lying on the line of equality. In all of the cases where the Bayesian and
frequentist heterogeneity estimates dier, the Bayesian estimates produced are
always greater than those obtained via the frequentist method. In fact, tting a
linear regression to the estimates, the Bayesian heterogeneity estimates are equal
to 0.107 plus 2.04 times the frequentist heterogeneity estimates.CHAPTER 4. FITTING A BAYESIAN MODEL 57
Figure 4.3. Comparing the Bayesian estimates with the frequentist estimates
(calculated using a macro in SAS) for the Binomial-Normal model
4.5.3 The Normal-Normal Model
Previously, the results from the Bayesian Binomial-Normal model (model 4.1)
were compared to the frequentist values. Here, we compare the values produced
for the heterogeneity from the Bayesian Normal-Normal model (model 4.9) and
the frequentist results. Non-informative priors were used for the overall treatment
eect (  N(0.0, 1,000,000)) and the heterogeneity (2  IG(0.001, 0.001)).CHAPTER 4. FITTING A BAYESIAN MODEL 58
Note model 4.9 uses the common ni's to calculate the 2
i's, however the results
produced in Table 4.5 use the given nCi's and nTi's, so the 2
i here are calculated
using
2
i =
1
rti
+
1
nti   rti
+
1
rci
+
1
nci   rci
All of the Bayesian results, displayed in Table 4.5 used a burn in of 5, 000
and then a further 25, 000 iterations for each of the two Markov chains. Once
again, two Markov chains were used to check visually that convergence of each
parameter did not produce any unexpected problems. The frequentist values
for the random eects between study variation, also displayed in Table 4.5 are
calculated using the moment estimate as used by DerSimonian and Laird (1986),
equation 2.2.
The results produced in table 4.5 indicate the Bayesian results using a Normal-
Normal model correspond quite well across the selected meta-analyses with the
two dierent frequentist results obtained via the methods used by DerSimonian
and Laird (1986) (equation 2.2) and Hardy and Thompson (1996) (equation
2.3). All of the frequentist heterogeneity estimates (excluding those estimated
as zero) are contained within the 95% C.I. for the Bayesian heterogeneity esti-
mate. The condence intervals for the Bayesian heterogeneity estimates for the
meta-analyses for which the frequentist heterogeneity estimates are zero all have
a lower estimate very close to zero (zero to two decimal places).
For meta-analyses with large numbers of trials and a large number of patientsCHAPTER 4. FITTING A BAYESIAN MODEL 59
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in each trial on average, one would generally expect the frequentist values for the
heterogeneity to produce similar results to those obtained computing the hetero-
geneity via Bayesian methods, as seen here. It is interesting to note however that
when the heterogeneity is zero, or is close to zero, the Bayesian and frequentist
values appear to agree fairly well, although more so if the number of clinical
trials is large. If the heterogeneity is not close to zero however, it appears the
Bayesian method produces a much larger estimate for the heterogeneity than the
frequentist method does.
The method used to calculate the frequentist heterogeneity values, equation
2.2, as used by DerSimonian and Laird (1986) seems to provide an accurate esti-
mate for the heterogeneity from a frequentist view with the results corresponding
well to the frequentist heterogeneity results produced for the meta-analyses us-
ing the maximum likelihood approach as used by Hardy and Thompson (1996),
equation 2.3.
Plotting the Bayesian results for the treatment eect estimates and the hetero-
geneity using the Normal-Normal model (model 4.9, with 2
i =
1
rti
+
1
nti   rti
+
1
rci
+
1
nci   rci
) against the corresponding values obtained via the two frequentist
methods, Figures 4.4, 4.5, and 4.6, will indicate whether the results do coincide
as one believes they should. Assuming the results agree exactly, one would an-
ticipate the points to lie on the line of equality, the dashed line in each of the six
plots. All of the plots use the number of studies as the grouping variable, with
the legend for the labelling of the groups beside each gure.
The rst gure, Figure 4.4 beolw, indicates the estimates for the treatmentCHAPTER 4. FITTING A BAYESIAN MODEL 61
Figure 4.4. Comparing the Bayesian estimates with the frequentist estimates
calculated using DerSimonian and Laird's method (equation 2.2)
eect using the Bayesian model (model 4.9 without using an averaged ni) coincide
almost exactly with the treatment eect estimates obtained using the method
used by DerSimonian and Laird (1986), with the estimates barely deviating from
the line of equality. Examining now the scatterplot for the heterogeneity values
calculated, it appears the Bayesian estimates are in general slightly greater than
those obtained using the frequentist method. Fitting a regression line to theCHAPTER 4. FITTING A BAYESIAN MODEL 62
heterogeneity estimates, the Bayesian heterogeneity values are equal to 0.0193
plus 1.43 times the frequentist heterogeneity values. The slope parameter, 1.43,
conrms the initial impression that the Bayesian estimates for the heterogeneity
are greater than those obtained via the frequentist method.
Figure 4.5. Comparing the Bayesian estimates with the frequentist estimates
calculated using Hardy and Thompson's method (equation 2.3)
Figure 4.5, which compares the Bayesian estimates with the frequentist esti-
mates calculated using the method used by Hardy and Thompson (1996) producesCHAPTER 4. FITTING A BAYESIAN MODEL 63
similar results to those noted from Figure 4.4. Like Figure 4.4, the treatment ef-
fect estimates computed using the Bayesian method, model 4.9, match almost
identically those computed using the method as used by Hardy and Thompson
(1996). The heterogeneity values however appear to dier between the two meth-
ods with the Bayesian values again being slightly greater than the corresponding
heterogeneity values. The tted regression for these two methods, Bayesian =
0.0431 + 1.61*frequentist, again conrms this, with a slightly larger slope pa-
rameter, 1.61.
Comparing now the two frequentist methods (DerSimonian and Laird (1986)
and Hardy and Thompson (1996)) displayed in Figure 4.6, the treatment eect
estimates appear to agree in almost every meta-analysis with just a small dif-
ference occurring in the meta-analyses which do not agree. The estimates for
the heterogeneity do not agree as well as noted in the treatment eect estimates,
however tting a regression line for the estimates computed using the method
used by DerSimonian and Laird (1986) against the method used by Hardy and
Thompson (1996), the intercept produced is 0.0249, with a slope parameter of
1.06, which is fairly close to one.
Figures 4.4, 4.5 and 4.6 indicate that no two methods of the three considered
agree exactly with any other 100% of the time, however of the three methods,
the two which match the closest appear to be the two frequentist methods, espe-
cially for the heterogeneity estimates, with the Bayesian heterogeneity estimates
appearing to have slightly larger estimates than either of the two frequentist
methods.CHAPTER 4. FITTING A BAYESIAN MODEL 64
It is apparent that the results via both the frequentist methods and the
Bayesian method for the treatment eect estimates correspond fairly well in
the majority of the meta-analyses. In the event of a dierence occurring, the
magnitude of the dierence is minimal.
Figure 4.6. Comparing the two frequentist approaches using estimates cal-
culated using DerSimonian and Laird's method (equation 2.2) and Hardy and
Thompson's method (equation 2.3)
On examination of the results for the heterogeneity, there is more evidence of
disagreements occurring between the dierent methods. The Bayesian methodCHAPTER 4. FITTING A BAYESIAN MODEL 65
appears to produce slightly larger measures for the heterogeneity than either the
DerSimonian and Laird method for calculating the heterogeneity or the method
of maximised likelihood as used by Hardy and Thompson.
4.5.4 Summary
Two dierent Bayesian models, a Binomial-Normal model and a Normal-
Normal model were tted to the data for all 125 meta-analyses, along with the
corresponding frequentist models using a macro within SAS (nlmixed) for the
Binomial-Normal model and two dierent methods for calculating the hetero-
geneity in a Normal-Normal model (DerSimonian and Laird (1986) and Hardy
and Thompson (1996)). The results produced were then examined using dierent
methods and models. Since each model used the same data, one would expect the
results to be very similar, irrespective of which method was used to obtain them.
The results produced for both the overall treatment eect and the heterogeneity
for each meta-analysis were plotted in separate scatter plots allowing the results
from the dierent methods used to be compared.
The scatter plots indicated the overall treatment eect estimates for each
meta-analysis were very similar regardless of the method used to calculate them.
The estimates of the heterogeneity however diered slightly depending on which
method was used to estimate them, with the two frequentist methods used for the
Normal-Normal model (DerSimonian and Laird (1986) and Hardy and Thompson
(1996)) producing the most similar results. These results indicate when estimat-
ing the heterogeneity for a meta-analysis the results can dier slightly dependingCHAPTER 4. FITTING A BAYESIAN MODEL 66
on which method one has used. The estimates produced using a Bayesian method
tend to be slightly larger than the corresponding estimates produced using a fre-
quentist method.
4.6 Comparing the Models
It is of interest now to compare all of the results produced for the data in Table
4.1 for the dierent models, the Binomial-Normal and the Normal-Normal model,
as well as comparing the results that have been produced from the two dierent
methods, the Bayesian method and the frequentist methods. For simplicity here,
and since the previous results (Figure 4.6) indicated the two frequentist meth-
ods produced similar results, the results from only one frequentist method are
produced here, that of DerSimonian and Laird (1986).
Model
Binomial-Normal Model Normal-Normal Model
E() = -1.3944 E() = -1.3387
Frequentist SD() = 0.1929 SD() = 0.1863
E(2) = 0.4275 E(2) = 0.4428
E() = -1.419 E() = -1.346
Bayesian SD() = 0.2065 SD() = 0.202
E(2) = 0.555 E(2) = 0.5037
SD(2) = 0.24 SD(2) = 0.2234
Table 4.6. Results for the data used by Abrams and Sans o (1998) using the
two models 4.1 and 4.9 for the two dierent methods, the frequentist and the
Bayesian.
A summary of the overall treatment eect estimate and the heterogeneity forCHAPTER 4. FITTING A BAYESIAN MODEL 67
the two dierent models and the two dierent methods are produced in Table 4.6.
The Bayesian model used for the Normal-Normal model is model 4.9, with the 2
i's
calculated as in equation 4.8, whilst the Bayesian Binomial-Normal model results
are produced using model 4.1, with the non-informative priors which Abrams and
Sans o (1998) used for  (Uniform(-10, 10))and 2
i (Inverse-Gamma(3, 1)).
Examining the results produced in Table 4.6, the estimates for the overall
treatment eect are most similar within the columns, i.e. there is a larger dif-
ference in the size of the overall treatment eect estimate when comparing the
dierent types of models, the Binomial-Normal with the Normal-Normal, than if
one compares the dierent methods (the frequentist and the Bayesian) for each
model.
The estimate for the heterogeneity however, indicates the estimates are most
similar within the rows, i.e. there is a larger dierence in the size of the hetero-
geneity when comparing the dierent methods (the frequentist and the Bayesian)
than if one compares the dierent models, the opposite of what was indicated
from the estimate of the overall treatment eect.
The results for the dierent estimates of the heterogeneity are not what one
would expect. One would believe any dierences which occur in the calculation
of these estimates would be due to the decision of which type of model used to
calculate the estimates and expect the results to be very similar if not the same
regardless of which method was used. In actual fact, it appears that the results
for the treatment eect estimate agree with this reasoning, yet the results for
the heterogeneity indicate that regardless of which model is used, the BayesianCHAPTER 4. FITTING A BAYESIAN MODEL 68
results for the heterogeneity will always be greater than those corresponding to
the frequentist methods.
4.7 Fitting an Informative Prior
4.7.1 Introduction
So far in this thesis, only non-informative priors which assume no prior knowl-
edge of how a variable will behave have been implemented into the Bayesian
models, however informative priors are also commonly used.
In a meta-analysis context, if one is creating a model to produce estimates
for the overall treatment eect and the heterogeneity, as is the case here, some
believe an informative prior should be used for the heterogeneity since there is in
fact some prior knowledge about it.
For example, since the heterogeneity is a measure of variance, it would seem
reasonable to expect it to take values in the interval [0;1) and so a prior which re-
stricts the values produced to within this interval could be appropriate. (Spiegel-
halter et al., 2004)
Senn (2007b) wrote a response to Lambert et al. (2005) which claimed \no
applied statistician believes that [the treatment eect and the heterogeneity] are
independent", in which case non-informative priors on both the treatment eect
and the heterogeneity would not be of use either. Upon examination of the rela-
tionship between the treatment eect and the heterogeneity earlier in this thesis
(Chapter 3), there did appear to be a relationship between the two, with a largerCHAPTER 4. FITTING A BAYESIAN MODEL 69
range of heterogeneity values occurring for larger treatment eects.
4.7.2 Creating a New Model
f(j;;) =
1
 + jj
exp

 

 + jj

(4.11)
If now we consider creating a new informative prior which takes into account
the prior information that the heterogeneity should in fact be restricted to the
interval [0;1) as well as the treatment eect and the heterogeneity have some
sort of relationship, we might consider a prior which Senn (2007b) proposed, as
mentioned earlier.
rci  Bin(nci;pci)
rti  Bin(nti;pti)
logit(pci) =  i
logit(pti) =  i + i
i  N(;2) (4.12)
 i  N(0;1000000)
  N(0;1000000)
  Exp()
 =
1
 + jjCHAPTER 4. FITTING A BAYESIAN MODEL 70
In his paper, Senn (2007b) proposed an exponential prior for  using the
\conditional prior distribution", noted here in equation 4.11.
This is an exponential prior which \allows dependence of  on  [the pooled
log odds ratio] (Senn, 2007b)" and the resulting new model is displayed in model
4.12 for using this prior with the Binomial Normal model and displayed in model
4.13 for using this prior with the Normal Normal model.
In models 4.12 and 4.13,  and  are both given constants, with Senn (2007b)
suggesting values of  < 1 and small values of . Here, a value for  of 0.05 and
a value for  of 0.1 is used.
yi  N(i;2
i)
i  N(;2) i = 1;:::;k
  Unif( 10;10) (4.13)
  Exp()
 =
1
 + jj
Using the data from Abrams and Sans o (1998) which has previously been
used for the Binomial Normal model (model 4.1) and the Normal Normal model
(model 4.9) with non-informative priors, one can implement these models again,
this time with the informative exponential prior (models 4.12 and 4.13).CHAPTER 4. FITTING A BAYESIAN MODEL 71
4.7.3 Examining the Results
The results produced using this new informative exponential prior, for both
the Binomial Normal Bayesian model (model 4.12) and the Normal Normal
Bayesian model (model 4.13) are displayed here in Table 4.7.
Model
Binomial-Normal Model Normal-Normal Model
E() = -1.461 E() = -1.37
Bayesian SD() = 0.2099 SD() = 0.2075
E(2) = 0.5278 E(2) = 0.4508
SD(2) = 0.2655 SD(2) = 0.2419
Table 4.7. Results for the data used by Abrams and Sans o (1998) using the
two models with the informative exponential prior (models 4.12 and 4.13) for the
Bayesian method.
One can see from Table 4.7 that although the Binomial Normal results are
not hugely dierent to the results obtained using the Normal Normal model, the
Binomial Normal results are larger for both the overall treatment eect estimate
and the heterogeneity. This is consistent with the results found for the two
Bayesian models using the non-informative prior for the heterogeneity.
It is interesting to note that on using the informative exponential prior, the
mean value for  is slightly larger than the equivalent results using the non-
informative priors, however the mean value for 2 is slightly smaller than the
equivalent results using the non-informative priors.
A sensitivity analysis for dierent values of  and  ( small and  <1)
in models 4.12 and 4.13 were also computed to ensure the prior used was notCHAPTER 4. FITTING A BAYESIAN MODEL 72
sensitive to the choices of  and .
Ideally, one would like to be able to produce results using models 4.12 and
4.13 with the values for  and  coming from a distribution rather than using
set constants.
Altering model 4.12 slightly to illustrate how this would be achieved, the 
and the  have been replaced with [1] and [2] respectively to allow them to
come from a bivariate log-Normal distribution, as displayed in model 4.14.
rci  Bin(nci;pci)
rti  Bin(nti;pti)
logit(pci) =  i
logit(pti) =  i + i
i  N(;2)
 i  N(0;1000000)
  N(0;1000000)
  Exp() (4.14)
 =
1
expbeta[1] + expbeta[2]jj
[1 : 2]  MN(2;)
2  MN(3;2)
expbeta[i] = exp([i])
  Wishart2(
)CHAPTER 4. FITTING A BAYESIAN MODEL 73
To allow [1] and [2] to come from a bivariate log-normal distribution, the
exponentials of the i's need to be used in the calculation of , the parameter
for the exponential prior on . The Bivariate Normal distribution for the 's has
parameters 2, a vector of length 2 which comes from a Bivariate Normal, and
, a 2 x 2 matrix which has a Wishart distribution here.
The priors placed on 3, 2 and 
 for model 4.17 above are restricted so
that the values obtained for expbeta[1] and expbeta[2] are restricted to follow
the suggested values of expbeta[1] small and expbeta[2] < 1 as discussed in Senn
(2007b).
Implementing model 4.14 using again the data from Abrams and Sans o (1998),
the matrix parameter for the Wishart distribution 
 is diag(1), 3 is a zero vector
of length 2 and 2 is a diag(100) matrix. The results are displayed in Table 4.8.
One can see on comparison with the previous results which used given values
for the hyperparameters,  and  (0.05 and 0.1 respectively), the computed values
for the treatment eect, , and the heterogeneity, 2 are again quite similar.
Model
Binomial-Normal Model
E() = -1.446
Bayesian SD() = 0.2332
E(2) = 0.7626
SD(2) = 0.4099
Table 4.8. Results for the data used by Abrams and Sans o (1998) using the
informative exponential prior for  with non-informative hyperparameters (model
4.14).CHAPTER 4. FITTING A BAYESIAN MODEL 74
The value for the treatment eect, -1.446, remains close to the estimates re-
ported in Table 4.7, whilst the value for the heterogeneity, 0.7626, is just slightly
greater than both of the previous results for the heterogeneity in Table 4.7. Al-
though the size of the heterogeneity estimate is fairly similar to the previous
estimates, it could be slightly bigger due to the model being more complex and
only the same amount of information being available.
4.7.4 Summary
As previously discussed in Chapter 3, there appears to be a relationship be-
tween the overall treatment eect of a meta-analysis and its corresponding het-
erogeneity. Senn (2007b) had also previously considered this and suggested the
use of an exponential prior on  (the square root of the heterogeneity) which was
also conditional on the overall treatment eect for that meta-analysis (equation
4.11). Senn (2007b) suggested the values for  to be small and  < 1. This new
prior for  was implemented using both a Binomial-Normal model (model 4.12)
and a Normal-Normal model (model 4.13). The results were fairly consistent
with the results previously calculated in Section 4.3, with the Binomial-Normal
model having a slightly larger value for both the overall treatment eect estimate
and the heterogeneity.
Hyperparameters were then added to allow the estimates for  and  to be
obtained from their own parameters. A Bivariate log-Normal distribution for
 and  was implemented with similar results to the previous results from the
model with the exponential prior on  but with given values for  and . TheCHAPTER 4. FITTING A BAYESIAN MODEL 75
obtained value for the heterogeneity was slightly larger, although that could be
due to a more complex model being tted with no more additional data.
4.8 A Meta-Analysis of Meta-Analyses
4.8.1 Introduction
So far, meta-analyses of various clinical trials concerning the same treatment
have been examined using two approaches, the frequentist and the Bayesian. It
is of interest now however to consider whether or not a meta-analysis of meta-
analyses can be computed using a Bayesian hierarchical model.
4.8.2 Creating the Model
To produce a meta-analysis of meta-analyses, the model will follow a hi-
erarchical format with k clinical trials (j = 1;:::;k ) and m meta-analyses
(i = 1;:::;m), which is displayed in model 4.15.
This model allows the treatment eect, i;j in model 4.15, to dier by both
meta-analysis and clinical trial. The i's correspond to the overall treatment
eect for meta-analysis i, whilst the 2
i 's correspond to the heterogeneity for
meta-analysis i. The non-informative priors on each i and each 2
i allow these
estimates to vary independently between each meta-analysis assuming there is no
prior knowledge on how these parameters should behave.CHAPTER 4. FITTING A BAYESIAN MODEL 76
rci;j  Bin(nci;j;pci;j)
rti;j  Bin(nti;j;pti;j)
logit(pci;j) =  i;j
logit(pti;j) =  i;j + i;j
 i;j  N(0;i) (4.15)
i  IG(0:001;0:001)
i;j  N(i;2
i )
i  N(0;1000000)
2
i  IG(0:001;0:001)
4.8.3 Examining the Results
Using the data which has been provided for 125 independent meta-analyses,
some, or even all of the data available, can be used with this new model, model
4.15 displayed above.
Selecting a subset of the meta-analyses available, for example all 11 of the
meta-analyses which have the eld myocardial infarction, these can be used with
the latest model, model 4.15, the results of which are displayed in Table 4.9.
Examining the results from the meta-analysis of the 11 myocardial infarction
meta-analyses, the meta-analyses with a large absolute treatment eect (i) also
have a corresponding large variance (2
i ) as one would expect. In table 4.9,CHAPTER 4. FITTING A BAYESIAN MODEL 77
Number
of trials i 2
i
in MA i
51 E(1) = -0.1411 SD(1) = 0.0635 E(2
1) = 0.0105 SD(2
1) = 0.0163
17 E(2) = -0.2201 SD(2) = 0.0622 E(2
2) = 0.0179 SD(2
2) = 0.0213
16 E(3) = 0.0877 SD(3) = 0.1358 E(2
3) = 0.0290 SD(2
3) = 0.0636
6 E(4) = 0.00096 SD(4) = 0.0716 E(2
4) = 0.0126 SD(2
4) = 0.0326
7 E(5) = -0.2798 SD(5) = 0.1147 E(2
5) = 0.0250 SD(2
5) = 0.0676
13 E(6) = -0.178 SD(6) = 0.0801 E(2
6) = 0.0192 SD(2
6) = 0.0377
11 E(7) = -0.7692 SD(7) = 0.319 E(2
7) = 0.5516 SD(2
7) = 0.5249
13 E(8) = -0.5274 SD(8) = 0.2567 E(2
8) = 0.4658 SD(2
8) = 0.3883
7 E(9) = -0.6276 SD(9) = 0.3551 E(2
9) = 0.2446 SD(2
9) = 0.6125
12 E(10) = -0.2517 SD(10) = 0.1052 E(2
10) = 0.0203 SD(2
10) = 0.0396
34 E(11) = -0.2856 SD(11) = 0.0683 E(2
11) = 0.0297 SD(2
11) = 0.0371
Table 4.9. Results for the Meta-Analysis of the 11 Meta-Analyses which all have
the same eld, myocardial infarction, using non-informative priors.
meta-analyses 7, 8 and 9 all have quite a large absolute treatment eect and
corresponding variance which is also quite large compared to the variances of the
meta-analyses with smaller absolute treatment eects.
4.8.4 A More Complex Model
The previous model (model 4.15) has been created using non-informative pri-
ors, however these can be changed to informative priors if one believes there is
some prior information, as has been demonstrated previously in Chapter 4 sec-
tion 7 (model 4.12).
The informative prior used previously for  (the square root of the heterogene-
ity) in model 4.12 was an exponential prior and this may be used here instead ofCHAPTER 4. FITTING A BAYESIAN MODEL 78
the non-informative Inverse-Gamma prior for the heterogeneity.
Computing this more complex model to now include an informative exponen-
tial prior, as noted in model 4.16 below, the same subset of meta-analyses which
was used for the previous model, model 4.15, can be used to compute results for
implementing a more informative prior.
rci;j  Bin(nci;j;pci;j)
rti;j  Bin(nti;j;pti;j)
logit(pci;j) =  i;j
logit(pti;j) =  i;j + i;j
 i;j  N(0;i) (4.16)
i  IG(0:001;0:001)
i;j  N(i;2
i )
i  N(0;1000000)
i  Exp(i)
i =
1
 + jij
Model 4.16 uses the same restrictions for the values of  and  that model
4.12 used, with  and  taking the same values here, 0.05 and 0.1 respectively.
Looking at the results produced using model 4.16, displayed in Table 4.10CHAPTER 4. FITTING A BAYESIAN MODEL 79
Number
of trials i 2
i
in MA i
51 E(1) = -0.1384 SD(1) = 0.0609 E(2
1) = 0.0035 SD(2
1) = 0.0070
17 E(2) = -0.2212 SD(2) = 0.0557 E(2
2) = 0.0081 SD(2
2) = 0.0116
16 E(3) = 0.0925 SD(3) = 0.1105 E(2
3) = 0.0054 SD(2
3) = 0.0123
6 E(4) = 0.0026 SD(4) = 0.0595 E(2
4) = 0.0034 SD(2
4) = 0.0071
7 E(5) = -0.2714 SD(5) = 0.0991 E(2
5) = 0.0075 SD(2
5) = 0.0149
13 E(6) = -0.1767 SD(6) = 0.0694 E(2
6) = 0.0054 SD(2
6) = 0.0106
11 E(7) = -0.7742 SD(7) = 0.2877 E(2
7) = 0.2594 SD(2
7) = 0.2153
13 E(8) = -0.5458 SD(8) = 0.2562 E(2
8) = 0.2098 SD(2
8) = 0.1772
7 E(9) = -0.6516 SD(9) = 0.3023 E(2
9) = 0.0288 SD(2
9) = 0.0764
12 E(10) = -0.2427 SD(10) = 0.0929 E(2
10) = 0.0061 SD(2
10) = 0.0120
34 E(11) = -0.2668 SD(11) = 0.0588 E(2
11) = 0.0133 SD(2
11) = 0.0195
Table 4.10. Results for the Meta-Analysis of the 11 Meta-Analyses which all
have the same eld, myocardial infarction, using an informative exponential prior
for .
below, one can see the results for the absolute treatment eects for the same meta-
analyses are quite similar to the previous results for the same meta-analyses using
a non-informative prior on the heterogeneity (Table 4.9), as one would expect.
One can also note the apparent reduction (by at least a half) for the expected
heterogeneity values using the informative exponential prior compared to using
the non-informative Inverse-Gamma prior.
Ideally, as mentioned before, a model which allows the parameters of the
exponential prior,  and , to come from a bivariate log-normal distribution
rather than using given values would be preferable, as displayed in model 4.17.
Using the same 11 meta-analyses that have previously been used for modelCHAPTER 4. FITTING A BAYESIAN MODEL 80
4.16, but this time instead of specifying constant values for  and  in model
4.16, which correspond to expbeta[1] and expbeta[2] here respectively, model
4.17 below allows these parameters to come from a non-informative Bivariate
Log-Normal model.
rci;j  Bin(nci;j;pci;j)
rti;j  Bin(nti;j;pti;j)
logit(pci;j) =  i;j
logit(pti;j) =  i;j + i;j
 i;j  N(0;i)
i  IG(0:001;0:001)
i;j  N(i;2
i ) (4.17)
i  N(0;1000000)
i  Exp(i)
i =

1
expbeta[1] + (expbeta[2]jij)

[1 : 2]  MN(2;)
2  MN(3;2)
expbeta[i] = exp([i])
  Wishart2(
)
Implementing the same priors on 3, 2 and 
 as previously done for modelCHAPTER 4. FITTING A BAYESIAN MODEL 81
4.14 to ensure the obtained values for expbeta[1] and expbeta[2] follow the values
as previously suggested (Senn, 2007b), the results using model 4.17 below are
displayed in Table 4.11.
One can see from these results that the values produced for both  and  are
very similar to the earlier computed results when using given values for  and
 (displayed in Table 4.10). The computed values for the parameters expbeta[1]
and expbeta[2], which correspond to  and  respectively from model 4.16 are
0.0497 and 0.4538, which are quite similar to the values for  and  which were
used to produce the results displayed in Table 4.10.
Number
of trials i 2
i
in MA i
51 E(1) = -0.1427 SD(1) = 0.0575 E(2
1) = 0.0054 SD(2
1) = 0.0105
17 E(2) = -0.2232 SD(2) = 0.0584 E(2
2) = 0.0132 SD(2
2) = 0.0180
16 E(3) = 0.0834 SD(3) = 0.1234 E(2
3) = 0.0111 SD(2
3) = 0.0275
6 E(4) = -0.0002 SD(4) = 0.0632 E(2
4) = 0.0042 SD(2
4) = 0.0118
7 E(5) = -0.2700 SD(5) = 0.1086 E(2
5) = 0.0148 SD(2
5) = 0.0334
13 E(6) = -0.1745 SD(6) = 0.0749 E(2
6) = 0.0099 SD(2
6) = 0.0232
11 E(7) = -0.8135 SD(7) = 0.3033 E(2
7) = 0.4503 SD(2
7) = 0.4061
13 E(8) = -0.5956 SD(8) = 0.2458 E(2
8) = 0.3617 SD(2
8) = 0.2977
7 E(9) = -0.666 SD(9) = 0.3073 E(2
9) = 0.1135 SD(2
9) = 0.2900
12 E(10) = -0.2335 SD(10) = 0.0955 E(2
10) = 0.0123 SD(2
10) = 0.0243
34 E(11) = -0.2771 SD(11) = 0.0650 E(2
11) = 0.0230 SD(2
11) = 0.0306
expbeta[1] = 0.0497 expbeta[2] = 0.4538
Table 4.11. Results for the Meta-Analysis of the 11 Meta-Analyses which all
have the same eld, myocardial infarction, using an informative exponential prior
for  with Bivariate Log-Normal hyperparameters.CHAPTER 4. FITTING A BAYESIAN MODEL 82
4.8.5 Summary
Having previously used several dierent models to obtain meta-analysis re-
sults, it was of interest to determine whether a meta-analysis of several meta-
analyses could be obtained. A simple Bayesian model was produced to model this
which rst used non-informative priors for the estimates of interest, the overall
treatment eects and the heterogeneities for each meta-analysis. Using 11 of the
available 125 meta-analyses which all had the same eld, myocardial infarction,
the model was implemented and results were obtained. The results for each of
the individual meta-analyses indicated the parameters of interest using the meta-
analysis of meta-analyses resulted in very similar estimates as those produced via
individual meta-analyses, the results of which have been attached in Appendix
A. The estimates which did dier the most between a simple meta-analysis model
and a meta-analysis of meta-analyses model occurred for the meta-analyses which
had larger corresponding standard deviations unsurprisingly. This did not seem
to occur for only the meta-analyses which had a small number of clinical trials
included.
A more complex model was then tted which included an exponential prior
on  as previously examined in Section 4.7, rstly with given values for  and 
and secondly allowing  and  to come from a Bivariate log-Normal model with
hyperparameters.
Implementing the exponential prior on  resulted in a reduction in the size
of the heterogeneity for each meta-analysis, with the model using given valuesCHAPTER 4. FITTING A BAYESIAN MODEL 83
for the hyperparameters  and  reducing the heterogeneities slightly more than
the Bivariate-Log-Normal distribution on the hyperparameters. The estimates
for the treatment eect estimates were all similar regardless of the model used.
This was expected since the parameter for the treatment eect estimates did not
change from a non-informative prior.Chapter 5
Conclusions and Discussions
Meta-analysis is a technique which can be used to combine the individual
treatment eects for several individual studies to obtain a single overall treatment
eect estimate. They are used for various dierent elds of interest - medical,
agricultural and educational research to name a few - and suit data of any form,
normally distributed data, ordinal data, survival data and binary data.
The methodology for combining the individual trial estimates, regardless of
the format in which the data arises, includes using a xed eects model, or a
random eects model, with the random eects model incorporating the hetero-
geneity into the xed eects model. The choice of which model should be used
is still debateable, with some statisticians believing the xed eects approach
suits their work better, whereas another might prefer to use the random eects
approach. Regardless of the approach used, the heterogeneity should be checked
for, and if need be, incorporated into the model to prevent an invalid result.
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The treatment eect estimates may be calculated numerically using a fre-
quentist approach such as the Mantel-Haenszel odds ratio for binary data, with
an additional random eects weight should the random eect model be used, or
using a more complex Bayesian approach which calculates estimates using the
data provided and specied priors.
The Mantel-Haenszel odds ratio calculates the odds ratio using a Normal ap-
proximation of the binary data, eectively losing the Binary format of the data,
however the Bayesian model would account for the Binary format from which the
data initially arose.
There are several measures of heterogeneity. Perhaps two of the better known
frequentist methods are DerSimonian and Laird's method of moments (DerSimo-
nian and Laird, 1986) and Hardy and Thompson's method based on the Max-
imum Likelihood estimators (Hardy and Thompson, 1996). The data used for
this thesis used both of these methods when obtaining frequentist heterogeneity
estimates and found the methods coincided extremely well.
The priors for a Bayesian model can be non-informative if no prior knowledge
is held or informative if there is some prior knowledge which the priors should ac-
count for. There are several choices of non-informative priors available, however
just how non-informative these priors actually are has been questioned (Lambert
et al., 2005). The general agreement is regardless of the prior chosen, a sensitivity
analysis should be performed to check the robustness of the results across various
non-informative priors.
Previously when meta-analyses have been performed, the two main areas ofCHAPTER 5. CONCLUSIONS AND DISCUSSIONS 86
interest, the overall treatment eect estimate and the heterogeneity, if a random
eects model has been used, are considered to be independent estimates and have
generally been modelled as such (Smith et al. (1995), Abrams and Sans o (1998)),
although this assumption has in fact been questioned (Senn, 2007b).
These estimates were calculated for 125 independent meta-analyses and upon
examination of these estimates, it appears a relationship between them does oc-
cur.
The data used for the purpose of this thesis was binary and estimates for all
three main metrics for binary data, the log-odds-ratio, the log-relative risk and
the risk dierence, were calculated using the frequentist approach. The results
when graphed indicated a positive correlation could occur between the treatment
eect estimate and the heterogeneity, regardless of which metric was chosen,
with increasing heterogeneity occurring for an increasing treatment eect esti-
mate. Correlations between the treatment eect estimates and the heterogeneity
for each metric separately were also computed and the results indicated a signi-
cant positive correlation of approximately 0.4 occurred irrespective of the metric
chosen.
A Bayesian model was then considered with separate non-informative priors
initially for the treatment eect estimate and the heterogeneity as have pre-
viously been used (Lambert et al. (2005), (Gelman, 2006), Abrams and Sans o
(1998), Smith et al. (1995)) before going on to t an informative exponential
prior on the square root of the heterogeneity which would allow the variance to
depend upon the overall treatment eect estimate.CHAPTER 5. CONCLUSIONS AND DISCUSSIONS 87
The rst Bayesian model which made use of non-informative priors for the pa-
rameters of interest and allowed the data to retain its binary format indicated the
treatment eect estimates using the Bayesian model with non-informative priors
corresponded very well to the estimates obtained using a frequentist Binomial-
Normal model. The estimates for the heterogeneity however indicated a slight
discrepancy between the Bayesian method and the frequentist method, with the
Bayesian method resulting in slightly larger estimates which increased with in-
creasing heterogeneity.
A Bayesian model using a Normal approximation for the log-odds ratios was
then implemented and compared to the results obtained using two frequentist
methods for the heterogeneity. Again the results for the treatment eect estimates
corresponded very well whether the Bayesian method or the frequentist method
was used. The estimates of the heterogeneity for the Bayesian method were again
slightly larger than those obtained using a frequentist method, although these es-
timates did not increase quite as much with the increasing heterogeneity values
compared to the models which kept the data in its Binary format.
Data for a meta-analysis using 22 studies which had been previously published
(Abrams and Sans o, 1998) was then used with all four combinations of model: a
Bayesian model using the Binary format, a Binomial-Normal model; a frequen-
tist model using the Binary format, a Binomial-Normal model; a Bayesian model
using a Normal approximation, a Normal-Normal model; a frequentist model
using a Normal approximation, a Normal-Normal model. The results for the
overall treatment eect estimate appeared to dier the most between the modelsCHAPTER 5. CONCLUSIONS AND DISCUSSIONS 88
used - the Binomial-Normal and the Normal-Normal, regardless of whether the
Bayesian approach or the frequentist approach was used, whereas the heterogene-
ity estimate diered the most between the approaches used - the Bayesian or the
frequentist.
Having examined the results for the dierent methods and models, it would
appear reasonable for one to conclude that if the person constructing the meta-
analysis is doing so under the assumption that the treatment eect estimate and
the heterogeneity are independent, then the advantage of the Bayesian model
is minimal and is perhaps not worth the extra eort since the treatment eect
estimates reported for the frequentist method and the Bayesian method are very
similar.
However, the estimates of interest appear to be related, and so the exponen-
tial prior for the square root of the heterogeneity which is dependant upon the
overall treatment eect estimate was implemented. Using given suggested values
for the two hyperparameters  and  (Senn, 2007b), the results obtained were
similar to those which were produced using the non-informative priors for both
the treatment eect estimate and the heterogeneity, with the Binomial-Normal
model having slightly larger estimates than the Normal-Normal model.
Despite the results after implementing the informative exponential prior re-
maining similar to those obtained using non-informative independent priors for
the treatment eect estimate and the heterogeneity, I would recommend if per-
forming a meta-analysis that one should use the Bayesian method, which allows
the user to include a subjective opinion, with the informative exponential priorCHAPTER 5. CONCLUSIONS AND DISCUSSIONS 89
rather than the non-informative independent priors since a relationship between
the treatment eect estimate and the heterogeneity has been indicated and there-
fore should not be ignored.
After then introducing a Bivariate-Log-Normal prior for the hyperparameters
 and , the results were again similar, with the heterogeneity value remaining
slightly larger. This may however be the result of a more complex model being
tted with no more additional data becoming available. The priors for the hy-
perparameters for the Bivariate-Log-Normal distribution were carefully selected
so that the parameters corresponding to the previous  and  parameters were
restricted so as not to deviate from the suggested given values (Senn, 2007b),
however more work focusing on the values which  and  take, whether they are
specied as given in the model or if they are the result of tting priors to these
values, should perhaps be done in an attempt to determine how sensitive a model
as complex as this one is.
An appropriate model for meta-analyses, I believe, should take into consid-
eration that the treatment eect estimate and the heterogeneity appear to be
related. Using Bayesian methods will allow this prior knowledge to be incorpo-
rated into the model as has been done in this thesis whilst using an informative
exponential prior.
As previously mentioned in the aims of this thesis, a meta-analysis involves
combining several independent clinical trials which are all alike allowing the treat-
ment eect to be transferred between the clinical trials. It may also be reasonable
to consider trials which have the same eld but dierent treatments, so long asCHAPTER 5. CONCLUSIONS AND DISCUSSIONS 90
care is taken when stating the hypotheses, looking at the modelling and the inter-
pretation of the results as discussed in Senn (2007a). By carefully considering the
modelling of the meta-analysis, one allows the treatment eect to be transferred
only between the trials which consider the same treatment eect.
11 Meta-analyses which all had the same eld, myocardial infarction, were
then used in a meta-analysis of meta-analyses. Although the clinical trials which
make up the 11 meta-analyses here all have the same eld, they do not necessarily
all examine the same treatments or the same concentrations. The results for the
same models as were previously used (one which uses non-informative priors for
the overall treatment eect estimates and the heterogeneity's, another which uses
the exponential prior for the square root of the heterogeneity and given values for
the hyperparameters  and , and another which allows  and  to come from
a Bivariate-Log-Normal model) were obtained.
All three models produced results for the treatment eect estimates and the
heterogeneity's which were similar to the results obtained via individual meta-
analyses. Some estimates diered a bit more between the models than others and
these appeared to be the meta-analyses which had larger corresponding standard
deviations for their estimates and not necessarily due to the number of clinical
trials which were included in the meta-analyses. As mentioned previously, the
nal most complex model which had a Bivariate-Log-Normal for the  and 
parameters were restricted so that the  and  did not dier too much from
suggested values (Senn, 2007b), although more work on these suggested values
could be done to check this restriction does not limit the results. It might also beCHAPTER 5. CONCLUSIONS AND DISCUSSIONS 91
worthwhile considering whether a dierent distribution would better suit these
priors and what eect, if any, the change in prior alters the parameters and if
this alters the results found here.
An idea for future work would be to further examine constructing meta-
analyses which consider clinical trials with dierent treatments. This could be
done by examining the variance of a clinical trial when it is included in a meta-
analysis which looks at trials with the same treatment and comparing the results
to a meta-analysis which looks at trials with dierent treatments.Appendix A
Individual Meta-Analysis Results
The results from the 11 individual meta-analyses, which all have the same
eld myocardial infarction, which were subsequently used in the meta-analysis of
meta-analyses are displayed here in table A.1. Model 4.1 was used to produce
the results and a burn-in of 5000 was used for each meta-analysis followed by
another 25,000 iterations using two chains.
The prior for 2 is slightly dierent to that in model 4.1, using an IG(0:001;0:001)
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Number
of trials i 2
i
in MA i
51 E(1) = -0.1125 SD(1) = 0.0658 E(2
1) = 0.0119 SD(2
1) = 0.0178
17 E(2) = -0.2100 SD(2) = 0.0634 E(2
2) = 0.0179 SD(2
2) = 0.0212
16 E(3) = 0.1344 SD(3) = 0.1388 E(2
3) = 0.0314 SD(2
3) = 0.0722
6 E(4) = 0.0062 SD(4) = 0.0726 E(2
4) = 0.0132 SD(2
4) = 0.0280
7 E(5) = -0.2589 SD(5) = 0.1165 E(2
5) = 0.0247 SD(2
5) = 0.0679
13 E(6) = -0.1591 SD(6) = 0.0805 E(2
6) = 0.0211 SD(2
6) = 0.0444
11 E(7) = -0.7069 SD(7) = 0.3066 E(2
7) = 0.5387 SD(2
7) = 0.5596
13 E(8) = -0.4691 SD(8) = 0.2593 E(2
8) = 0.4568 SD(2
8) = 0.3970
7 E(9) = -0.5465 SD(9) = 0.3752 E(2
9) = 0.2867 SD(2
9) = 0.7324
12 E(10) = -0.2246 SD(10) = 0.1016 E(2
10) = 0.0196 SD(2
10) = 0.0358
34 E(11) = -0.2610 SD(11) = 0.0614 E(2
11) = 0.0253 SD(2
11) = 0.0311
Table A.1. Results for the 11 individual Meta-Analyses which all have the same
eld, myocardial infarction, using a slightly altered model 4.1 (see footnote)References
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